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Hepcidin: from discovery to differential diagnosis
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Introduction 
1. Iron 
1.1 Iron: essential and harmful 
Iron is an element that is interwoven with our daily environment because of its 
abundance in the earth’s crust1,2.  Its capacity to participate in one-electron transfer 
and acid-base reactions, explains why iron is indispensable and thus essential for 
life. 
For survival and proliferation eukaryotic cells and most prokaryotic organisms require 
iron, as a constituent of oxygen binding heme proteins, iron-sulfur proteins, and 
proteins that use iron in other functional groups to carry out essential functions for 
cellular metabolism. Therefore, cellular iron deficiency stops cell growth and even 
might lead to cell death. 
However, a side effect of the reactive properties of iron can also lead to cell damage. 
Fe2+ is capable of catalyzing the generation of highly reactive hydroxyl radicals from 
hydrogen peroxide, which is called the ‘Fenton reaction’3; a condition that especially 
occurs during iron overload. Besides the functional role of radical formation in cell 
signaling pathways, these radicals damage cellular membranes, proteins, and DNA. 
In order to combine life with a potential toxic primal element, evolution has provided 
us with a large number of deeply integrated regulation systems and scavenger 
molecules that protect against iron mediated tissue damage, and by which the body 
is challenged to carefully control iron within its functional limits4. 
 
1.2 Maintenance of body iron homeostasis 
In humans, approximately two third of the total body iron is utilized in hemoglobin, 
with the rest in myoglobin, respiratory enzymes, and stored as hepatic ferritin. As 
displayed in Figure 1A, body iron metabolism is based on a highly efficient system of 
iron conservation and recycling by which only up to a 10th of the daily need is 
replaced by duodenal absorption from diet. Excess iron is either not absorbed, or is 
retained in enterocytes. After approximately 2 days these cells are shed from the tips 
of the villi into the luminal intestinal contents. This apparently regulated iron uptake 
and the absence of a physiological excretion mechanism makes it impossible to 
release excessive iron in case of iron overload. Most of the 20 to 25 mg iron that is 
required daily in the bone marrow for erythropoiesis, is recovered from senescent 
erythrocytes by macrophages in the spleen and released into the circulation where it 
is transported throughout the body, bound to transferrin. In case of increased iron 
demand due to high erythropoietic activity of the bone marrow or iron depletion, 
intestinal iron absorption and iron recruitment from hepatic stores increases. The 
maintenance of body iron homeostasis requires mechanisms to control iron uptake 
and mobilization from stores, in order to meet erythropoietic needs, and for 
scavenging previously used iron. Therefore the communication between cells that 
consume iron and cells that acquire and store iron must be tightly regulated4,5. 
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Figure 1. Iron uptake and recycling.  
(A) Most of the utilized body iron is recycled from senescent erythrocytes by macrophages, and 
returned to the bone marrow for incorporation in erythroid precursors. The liver and reticuloendothelial 
macrophages function as major iron stores. 1-2 mg of iron is absorbed and lost every day. Only 
duodenal absorption is regulated by transporters such as DMT1 and HCP1, whereas iron loss occurs 
passively. The liver produced peptide hepcidin controls the plasma iron concentration by inhibiting iron 
export by ferroportin from enterocytes (B) and macrophages (C). This implicates that an increased 
hepcidin production leads to a decrease in plasma iron concentrations. Hepcidin expression is 
regulated by body iron stores, inflammation, erythroid iron demand, and hypoxia via regulation 
pathways involving expression of HFE, TfR2,TfR1 and HJV genes. Details are discussed in the text 
and in figure 3. DMT1: divalent metal transporter 1; Hb: hemoglobin; HO: heme oxygenase; NTBI: 
non-transferrin bound iron; Tf: transferrin; Cp: ceruloplasmin; HCP1: heme carrier protein 1; DcytB: 
duodenal cytochrome B. Reproduced with permission in adapted form from Swinkels et al Clin Chem 
200677
 
As shown in Figure 1B, duodenal enterocytes absorb iron from the diet, where it is 
mostly present as ferric Fe3+ or as heme, a molecule that consist of a protoporphyrin 
ring that binds iron. After reduction on the apical surface of the enterocytes by 
duodenal cytochrome-b (Dcytb), iron enters the cell by divalent metal transporter-1 
(DMT-1). Heme is reported to be absorbed by a recently identified receptor heme-
carrier protein-1 (HCP-1) 6- also involved in folate uptake7- and released from iron by 
heme oxygenase-1 (HO-1). Once in the cell, iron is stored by ferritin and in case of a 
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high body demand for iron released into the plasma by the sole known cellular iron 
exporter ferroportin. After oxidation by ferroxidase hephaestin (intestinal cells) or 
ceruloplasmin (nonintestinal cells), iron is loaded onto transferrin for transport in the 
plasma were it is picked up by TfR1 on the cell surface of cells in need of iron. Next 
to dietary iron uptake, iron is recycled from senescent erythrocytes by macrophages 
(Figure 1C). Also here, HO-1 plays an important role in extracting iron from heme in 
the cytosol whereas involvement of DMT-1 is suspected but not proven8. Recent 
reviews on cellular iron uptake, storage and export are given by Hentze et al and 
Dunn et al 4,9. 
 
2. Hepcidin 
2.1 The discovery of hepcidin 
Although hepcidin was first discovered in human urine and serum, most data on 
hepcidin expression, regulation, structure and function were obtained by in vitro 
approaches and studies in mice, as reviewed in the next paragraphs. Hepcidin was 
initially isolated from plasma ultrafiltrate10 and named liver-expressed antimicrobial 
peptide (LEAP-1). Almost simultaneously, it was isolated from human urine and 
named hepcidin after its hepatic origin and bactericidal effect in vitro 11. The 
development of severe iron overload12 by knocking out the gene in mice suggested 
hepcidin to be involved in iron metabolism, whereas this key role in regulation was 
stressed by the discovery of hepcidin mutations in patients13. The newly discovered 
peptide was found to be regulated by inflammation, iron stores14, hypoxia and 
anemia15.  
 
 
2.2 Structure of hepcidin 
The human hepcidin gene (HAMP; OMIM 606464), located on chromosome 19q13.1, 
encodes a precursor protein of 84 amino acids (aa). In vitro experiments in murine 
hepatic cell lines showed that the production and localization of pre-prohepcidin is 
assumed to be intracellular in the secretory pathway16. During its export from the 
cytoplasm, this full-length pre-prohepcidin undergoes enzymatic cleavage of a 20 aa 
N-terminal endoplasmic reticulum-targeting signal peptide, resulting in the export of a 
64 aa prohepcidin peptide into the ER lumen17. Next, the 39 aa pro-region peptide is, 
most likely, posttranslational removed by a furin-like proprotein convertase11,18 in the 
trans-Golgi network, resulting in mature bioactive hepcidin-25 (25 aa form). Park et 
al, identified in human urine also hepcidin-22 and hepcidin-20, which are N-terminally 
truncated iso-forms of hepcidin-2511. Our recent results confirm that in addition to 
hepcidin-25, the 20 aa iso-form is detectable in both human urine and serum, while 
the 22 aa iso-form can only be detected in urine19. These results support the 
hypothesis that both the 20 and 25 aa peptides are secretory cell products, whereas 
the 22 aa peptide is merely an urinary degradation product of hepcidin-2520. It is 
currently unclear whether hepcidin-20 is functional, whether it is produced by 
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hepatocytes or other cell types, if it originates from proteolysis of hepcidin-25 or from 
convertase-mediated differential processing of pro-hepcidin, and whether this event 
takes place before or after hepcidin is secreted by hepatocytes.  
Structural analysis by NMR spectroscopy of human synthetic hepcidin revealed that 
this small 8 cysteine-containing peptide forms a hairpin-shaped molecule with a 
distorted β-sheet which is stabilized by four disulfide bridges between the two 
antiparallel strands21. One of the disulfide bridges is located in the vicinity of the 
hairpin loop which points to a possible crucial domain in the activity of the molecule21 
(Figure 2). The high cysteine content of the molecule, and therefore the disulphide 
interconnections are highly conserved among other species11. Structure-function in 
vivo (mice) and in vitro studies on synthetic hepcidin have shown that the iron 
regulating bioactivity is almost exclusively due to the 25 aa peptide, suggesting that 
the five N-terminal amino acids are essential to exert this activity22,23. The typical β-
defensin structural conformation with amphipathic properties is a hallmark for 
antimicrobial activity24, and in vitro experiments have shown that especially human 
hepcidin-20 exerts antibacterial and antifungal activity in a concentration range 10-
fold higher than measured in healthy individuals10,11. Therefore, it is not clear whether 
in vivo hepcidin levels in the circulation or in urine of man can reach values in which it 
can be antimicrobial, and thus whether this function still is of biological importance or 
only rudimental of its evolutionary origin25,26. A recent report on inductively coupled 
plasma-mass spectrometry (ICP-MS) on human hepcidin-20 and -25, extracted from 
pooled urine samples showed co-purification of at least one iron molecule with 
hepcidin27. Modeling of a best-fit 3D structure of hepcidin with iron displayed 
significant differences with the previous reported synthetic hepcidin model21. These 
new insights suggest a conformational polymorphism for hepcidin as a regulatory 
mechanism for iron uptake as part of its role as regulator of iron homeostasis. Further 
research must reveal if this proposed iron binding property of hepcidin expands the 
regulation complexity of iron metabolism. 
 
 
2.3 Mechanism of hepcidin activity 
Recently, new light was shed on how hepcidin exerts its regulatory function on iron 
metabolism. It was reported to bind to the transmembrane iron exporter ferroportin28-
30 which is present on macrophages and the basolateral site of enterocytes (Figure 
1B and C), but also in hepatocytes. 
In vitro it has been demonstrated that next to binding, hepcidin subsequently induces 
the internalization and degradation of ferroportin31. It remains to be defined whether, 
as recently suggested32, structural properties such as amino terminal Cu and Ni 
binding (ATCUN) motifs in the hepcidin-25 molecule play a role in this process 
(Figure 2). For cellular iron export, the cell depends on ferroportin as originally 
demonstrated in zebrafish33. Moreover, in mice, ferroportin deletion was incompatible 
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with life34 whereas inactivation of the gene after birth leads to iron overload in 
hepatocytes, macrophages and enterocytes34. 
 
 
 
 
Figure 2. Molecule structure of human synthetic hepcidin-25.  
Front: overview of the structure of hepcidin-25. Distorted β-sheets are shown as grey arrows, and the 
peptide backbone is colored gray. The disulfide bonds are colored yellow, highlighting the position of 
an unusual vicinal bond between adjacent cysteines at the hairpin turn. Positive residues of Arginine 
(Arg)and Lysine (Lys) are pictured in blue, the negative residue of Aspartic acid (Asp) in red, and the 
Histidine containing amino terminal Cu2+- Ni2+(ATCUN)-binding motif in the N-terminal region is 
colored green. Background: hepcidin-25 molecule displayed with solvent accessible surface that 
illustrates the amphipathic structure of the molecule. The molecule is colored gray, except for the side-
chains of positive (blue) and negative (red) residues. Molecular graphics created with YASARA128 
(www.yasara.org) and PovRay (www.povray.org), with coordinates and factors obtained from the 
Protein Data Bank (www.rcsb.org ; PDB file code 1M4F). 
 
Thus, by diminishing the effective number of these iron exporters on the basolateral 
membrane of the enterocytes or on macrophages, hepcidin suppresses iron uptake 
and release, respectively. This is in line with the phenotype of ferroportin disease in 
which iron accumulation is observed mainly in macrophages often in combination of 
anemia35,36. 
Next to this systemic liver hepcidin controlled reduction of iron uptake and release, 
there is also evidence for local production of hepcidin by macrophages under 
inflammatory conditions37,38, or even production in fat cells39 and cardiomyocytes40. 
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These findings suggest different regulatory mechanisms to control iron imbalance in 
which hepcidin is involved.  
 
 
 
  
 
 
Figure 3. Model of pathways involved in hepcidin regulation. 
Displayed are the three active regulation pathways (erythropoietic activity derived regulation, iron store 
regulation, and inflammation regulation) and a mandatory signaling pathway that together control the 
hepcidin production in the liver cell. Erythropoiesis is under control of hypoxia induced erythropoietin 
production by the kidney. The bone marrow “communicates” by a thus fare unknown factor that is 
likely to interfere with the iron store regulation. This store regulation involves the circulating amount of 
transferrin bound iron that competes with HFE in binding to TfR1 hereby promoting formation of the 
TfR2/HFE complex as an inducer of hepcidin production. Direct influence of intracellular iron from the 
labile iron pool on hepcidin regulation is not clear yet. The inflammation regulatory pathway is foremost 
induced by IL-6 and is suggested to act more dominant regardless the activity of the other pathways. 
The HJV controlled BMP/SMAD signaling pathway appears to be mandatory for the activity of the 
store and erythropoiesis derived regulation. The metabolic syndrome candidate genes USF1 and 2 are 
in direct control of the HAMP gene, hereby suggesting a link between lipid, glucose, and iron 
metabolism. pO2: partial oxygen pressure; HIF: hypoxia inducible factor; CBP: CREB binding protein; 
EPO: erythropoietin; HNF: hepatic nuclear factor; TfR: transferrin receptor; sTfR: soluble TfR; HFE: 
hemochromatosis iron protein; β2M: beta-2 microglobuline; HJV: hemojuvelin; sHJV: soluble HJV; 
BMP: bone morphogenetic protein; BMPR: BMP receptor; P: phosphate; SMAD: mothers against 
decapentaplegic homologue (Drosophila); IL: interleukin; IL-6R: interleukin-6 receptor; gp: 
glycoprotein; JAK: Janus kinase; STAT: signal transducer and activator of transcription; TGF: 
transforming growth factor; USF: upstream stimulation factor; E: E-box; HAMP: hepcidin anti microbial 
peptide gene; CE-9: conserved element 9.  
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3. Hepcidin at the nexus of various regulatory pathways  
 
3.1 Upstream regulation 
Momentarily four putative upstream regulatory pathways that control liver hepcidin 
production have been described: i) iron store-related regulation, ii) erythropoietic 
activity driven regulation, iii) inflammation related regulation), and  iv) a mandatory 
signaling pathway. All are found to interact with liver cells to initiate the production of 
sufficient hepcidin for a proper maintenance of iron homeostasis41-46. In Figure 3 we 
depict a model of pathways involved in hepcidin regulation that builds upon recently 
acquired insights, in general derived from mice studies and in vitro cell culture work. 
The model is focused on three relevant sites involved in hepcidin regulation: kidney, 
bone marrow and liver cells. Notably, the iron efflux regulation in macrophages by 
hepcidin, just as skeletal muscles which express high levels of hemojuvelin are kept 
out of this picture. We will shortly discuss each of these 4 pathways in the following 
sections.  
 
3.1.1 Iron Store-related Regulation 
Information on the amount of iron in depot is communicated by a “store regulator” 5. 
How this stores regulator acts upon the hepcidin producing liver cells is unclear, 
although in vitro work on interactions between transferrin and the membrane 
proteins HFE, and transferrin receptor (TfR) 1 and 2 has lead to a hypothetical 
model in which circulating iron bound to transferrin, affects the formation of a 
complex of TfR2, and HFE on the surface of liver cells. This regulation mechanism is 
clarified in Figure 3 and the corresponding legend. This complex is capable of 
increasing the hepcidin production by a thus far unknown intracellular signaling 
pathway42,47.  
 
 
3.1.2 Erythropoietic activity-driven regulation 
An erythropoietic activity derived regulator is proposed to act as the communicator 
between the erythron and the liver5. In case of hypoxia or anemia, low oxygen 
pressure (pO2) levels induce hypoxia inducible factor (HIF)-1α stabilization in kidney 
cells, which results in erythropoietin (EPO) production of the kidney. EPO increases 
the erythropoietic activity and thus the need for iron of the bone marrow, resulting in 
a fast iron mobilization from the stores. This results in an increased duodenal iron 
absorption by diminishing the circulating hepcidin concentration regardless the 
status of the iron stores. This suggests that the erythropoietic activity derived 
regulation interacts with the store regulator and is able to control its effect on 
hepcidin induction. A suitable candidate for this role, reflecting the erythropoietic 
activity of the bone marrow, might be found in the soluble transferrin receptor (sTfR) 
molecule48. By competing with TfR2 in the binding to the HFE-β2 micro globulin 
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(β2M) complex on the cell surface of hepatocytes43,44,49,50 it is capable to interfere 
with the store regulator. However, to date this has not been proven51. 
 
3.1.3 Inflammation-related regulation 
A third upstream regulator of hepcidin is controlled by infection and inflammation. 
This “inflammatory regulator” pathway has lately been shown to be predominantly 
induced by interleukin (IL)-6 followed by Janus kinase (JAK)/Signal transducer and 
activator of transcription (STAT)-3 signalling45,46,52. It is suggested that this pathway 
might act more independently from the other pathways53-58 although results lack 
consensus on this matter59. Interactions between inflammation and HJV/BMP 
regulation through STAT-3 and SMADs as a result of TGF-β cell signalling60-62, 
illustrate the complexity of the signalling cascades involved in hepcidin 
regulation63,64.  
 
3.1.4 Mandatory signalling pathway 
A recent report hypothesized that the functional effect of both the store regulator and 
erythroid regulator fully depends on the activity of an additional pathway that is 
controlled by the glycosylphosphatidylinositol (GPI)-linked cell associated 
hemojuvelin (HJV). HJV has been suggested to maintain a mandatory regulation 
pathway by Bone Morphogenetic Protein (BMP)/SMAD signalling41 in which SMAD4 
seems to be essential65. Disruption of this pathway by HJV mutations cripples the 
functionality of both store and erythropoietic activity related regulation66, hereby 
claiming a critical role in hepcidin production. Next to the membrane-linked HJV, the 
presence of a soluble form was reported to be detectable in human serum53. This 
soluble HJV (sHJV) is suggested to be a cleavage product of the membrane-
anchored protein, and in some way under control of circulating iron57. In addition, in 
vitro experiments have shown that recombinant soluble hemojuvelin is capable of 
suppressing hepcidin mRNA expression. Together these data suggest an iron 
controlled binding competition between membrane-bound and sHJV that result in the 
control of hepcidin production67,68. However, many details of this mandatory hepcidin 
signaling pathway and its nexus with other regulatory pathways are still unknown. 
 
 
3.2 Transcriptional regulation 
Several transcription factors are reported as important for the Hepcidin promoter 
function such as C/EBPα69, hepatic nuclear factor (HNF4α)69, upstream stimulatory 
factor (USF)70  and p53 71 and probably cooperate to allow opening of the chromatin 
at the hepcidin locus and initiation of transcription. 
Simultaneously, some of these factors are also mentioned in association with 
metabolic syndrome72,73, alcohol metabolism-mediated oxidative stress74 and 
hypoxia75. Few are even under cyclical control (discussed by Bayele et al70) and may 
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also cooperate with the SMAD proteins activated by the HJV/BMP pathways. 
Involvement of the von Hippel-Lindau (VHL)/HIF-axis is recently reported76 as a 
possible regulation pathway related to erythropoietic activity. So far, nothing is 
known of the signaling pathway responding to the HFE-TfR2 interactions and its 
interference with ubiquitous or hepatic-specific transcription factors indicating that 
our understanding of this last step in hepcidin gene regulation is far from complete. 
Taken together, what once was considered as a regulation system with only a few 
roads now appears to be part of a complex regulatory network in which hepcidin is in 
fact a protein that has numerous irons in the fire. This complexity might preclude a 
clear prediction of the effects on mutations in upstream regulators of hepcidin. This 
is exemplified by the variable clinical penetrance of the homozygous C282Y 
alteration in the HFE-protein, which thus far remained largely unexplained77.  
 
4. Hepcidin kinetics  
After hepcidin is secreted into the circulation by the hepatocytes and performing its 
regulatory role in cellular iron uptake and release, it exits the body with the urine. Its 
effect on the decline in serum iron levels in mice appeared to take place within 4 
hours in a dose-dependent way that sustained for more than 48 hours22. Indirect 
hepcidin inductions by IL-6 or LPS in man displayed the same fast response in 
urinary hepcidin excretion78,79, thereby acting like an acute phase protein with a peak 
value after 6 hours, followed by a steady decline. The clearance of hepcidin from the 
circulation appears to be a process that occurs within 24 hours, as demonstrated in 
mice injected with radio-labeled hepcidin22. Oral iron administration for 3 days in 
healthy human volunteers showed a significant increase in urinary hepcidin after 24 
hours that disappeared in the following days despite the iron intake. The peak value 
in urine suggests a fast clearance of hepcidin from the circulation, with a paradoxical 
sustained inhibitory effect on iron uptake as displayed by the absence of change in 
iron parameters in the following days78.  
The fast appearance of hepcidin in urine illustrates the exceptional features of this 
peptide. Thus far tubular dysfunction or even reported tubular expression80 of 
hepcidin as a causative factor in hepcidinuria has not yet been studied. It is 
interesting to investigate the role of the kidney tubuli in the urinary hepcidin excretion 
as in several disorders of iron metabolism disturbed excretion might be expected 
such as (severe) inflammation81 and iron overload associated  tubular 
dysfunction82,83.  
 
5. Hepcidin: from mice to man 
Although highly homologous hepcidin genes have also been identified in many 
vertebrates including rodents like mice and rats, several species of fish, dogs and 
pigs, it should be noted that in mice two paralogous genes have been found from 
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which only hepcidin1 appears to be involved in iron metabolism84-86. As described in 
the previous paragraphs, mice have been a useful animal model to unravel pathways 
in iron metabolism, but amongst others these differences at the genetic level of 
hepcidin necessitates a careful extrapolation of results on hepcidin obtained in mice 
to that in man. Similarly, although in vitro systems allow a broad spectrum of 
interventions, the similarity to the human in vivo situation is restricted.  Therefore, 
measurement of circulating levels of hepcidin in man is important to increase our 
knowledge on the role of hepcidin in different pathological conditions (Table 1A). 
More specifically, these insights might add to the definition of hepcidin as a 
differential diagnostic tool and therapeutic target in human disease.  
 
5.1 Assessment of urinary and serum hepcidin in humans 
Until recently, only few investigative tools were available to detect hepcidin in human 
studies. Hepcidin mRNA expression is mostly preferred in animal and cell culture 
studies, but obviously very sporadically used in human studies because of the need 
of invasive sampling. Immunochemical methods based on the use of specific anti-
hepcidin antibodies, like in immuno-histochemical tissue staining, SDS-PAGE and 
Western Blot87,88 is largely hampered by the limited availability of suitable antibodies. 
This can be attributed to the small size of hepcidin, the compact and complex 
structure of the molecule and the highly conserved sequence among species, 
complicating the elicitation of an immune response in host species.  
In the next sections we will shortly describe and discuss the assays which are 
currently available to measure (pro)hepcidin in serum and/or urine. 
 
5.1.1 Antibody-based hepcidin assay 
To our knowledge, to date, only one antibody-based dotblot assay has successfully 
been used to (semi)quantify hepcidin in urine78,79. With the use of cation exchange 
chromatography, peptides are extracted from urine, eluted from the matrix, 
lyophilized, and resuspended in an acetic solution. Extracts are immobilized on a 
vinyl membrane by dotting, along with synthetic hepcidin standards. With the use of 
rabbit anti-human hepcidin primary antibodies87, and goat anti-rabbit horseradish 
peroxidase as a secondary antibody, the dots are quantified after 
Chemiluminescence detection. Hepcidin quantity in each sample is normalized using 
urinary creatinine concentrations, and expressed as nanogram hepcidin per milligram 
creatinine. However, due to its laborious procedure, and the use of relatively large 
sample volumes, this assay is not optimal for high-throughput measurements in large 
clinical studies. Absence of a control for hepcidin losses in the pre-analytical phase of 
the analysis like in the protein extraction step and resuspension step, might regard 
this assay as semi-quantitative. The limited availability of suitable antibodies which 
are mostly non-commercially made hampers the optimization of antibody-based 
assays with guaranteed specificity. On the other hand, a hepcidin ELISA will greatly 
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enhance the accessibility of the analysis, but it is not likely to be discriminative for the 
different isoforms of hepcidin.  
Next to bioactive hepcidin, the measurement of its precursor pro-hepcidin is reported 
with the use of a commercially available ELISA kit that uses antibodies directed 
against the pro-peptide region of the 64 aa precursor of hepcidin89. The diagnostic 
use of this assay is controversial because of the lack of clear correlations with 
hepcidin19,79 and other iron related parameters90-93. Significant concentration 
differences only have been reported in ferroportin disease94 or in combination with 
end stage renal disease (ESRD)95.  
 
5.1.2 Mass spectrometry-based hepcidin assay 
Recently we described a surface-enhanced laser desorption/ionization time-of-flight 
mass spectrometry (SELDI-TOF MS)-based assay that detects the three known 
isoforms of hepcidin96. More recently, analytical improvement has made this 
technique also suitable of measuring hepcidin-25 in serum19. Importantly, the 
procedure is fast; allowing the simultaneous analysis of large sets of human 
samples, but is difficult to robotize due to the on-spot procedure. The urinary 
Immobilized Metal Affinity Capture (IMAC)30 ProteinChip application has shown to 
correlate highly with the Normal Phase (NP)20 array application19, which in turn 
strongly correlated with the immuno-dotblot assay96. Latest improvement of the 
IMAC30 application include both a procedure to prevent hepcidin losses during 
sample preparation and the introduction of a hepcidin analogue as internal standard, 
which corrects for the analytical variation and excludes the sample matrix influence 
and allows sensitive quantification of hepcidin in both serum and urine samples (D. 
Swinkels and C. Laarakkers, unpublished results). 
The potency of MS-based hepcidin analysis is underscored by other recent 
reports97,98. Tomosugi and co-workers97 reported serum hepcidin measurements 
with the use of SELDI-TOF MS, but with the use of diluted serum samples and a 
bioprocessor. Compared to the aforementioned direct on-spot method, this 
application allows the combination with robotics. It uses synthetic human hepcidin-25 
to construct an external standard curve, but lacks the use of an internal standard and 
should therefore be regarded as semi-quantitative97. 
Another report on serum hepcidin analysis in only healthy subjects uses of liquid 
chromatography tandem mass spectrometry (LC-MS/MS)98 with a non-hepcidin 
related internal standard. Both methods still need highly specialized equipment, and 
therefore do not readily improve accessibility. Comparative studies, the use of 
uniform internal standards and accuracy adjustment of all techniques available to 
date might increase the comparability of results in the future. 
For the moment, mass spectrometry-based hepcidin measurements in serum and 
urine seem to be an attractive option to semi-quantify serum and urine hepcidin 
levels in clinical studies for research purpose only and in a small number of 
laboratories in the world.  
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Ongoing improvement of analysis techniques for hepcidin are essential to accurately 
assess levels of hepcidin and its isoforms in body fluids of different species, cell 
media and cell contents. This will contribute to the further unraveling of the hepcidin 
networks that are key for diagnostic and therapeutic approaches in man. 
 
5.2 Insights from hepcidin measurements in man  
The development and implementation of urinary and serum hepcidin assay’s allowed 
several clinical studies that increased the existing knowledge on hepcidin levels in 
physiologic and pathophysiologic states. In the next paragraphs, these studies will be 
discussed in view of previous related in vitro approaches and analogous studies 
using mice as model organisms. 
 
5.2.1 Pre-analytical factors and diurnal variation 
First of all, evaluation of our MS-based hepcidin measurements in human serum and 
urine samples revealed a substantial influence of pre-analytical factors on especially 
urinary hepcidin and a strong diurnal variation of serum hepcidin levels19. In line of 
agreement, Murphy et al98 found high between-day variation of serum hepcidin levels. 
Despite these variations we were able to differentiate various disorders of iron 
metabolism by the hepcidin values of sera and urines collected randomly throughout 
the day19. This indicates that the inter-individual variation in hepcidin levels is higher 
than the intra-individual variation. In mice, background influences like strain and 
gender have been shown to substantially modulate liver hepcidin mRNA’s99,100. In a 
small set of samples Murphy et al found no major differences in serum 
concentrations from normal male and female women98, which is in concordance with 
our findings in a different control group for both serum as urine values (data extracted 
from ref. 19). To the best of our knowledge urine and serum hepcidin levels have not 
been reported for non-Caucasian populations, and for children only once under 
pathological conditions101. 
 
5.2.2 Hepcidin regulation 
The involvement of hepcidin in the induction of hypoferremia by inflammation was 
translated from mice to human studies after the introduction of the urinary dotblot and 
the SELDI-TOF MS assays, which also demonstrated the existence of the highly 
responsive LPS- IL-6- hepcidin axis as a link between innate immunity and iron 
metabolism78, 79, 87.  
Erythropoietic activity appeared to be a strong regulator of hepcidin levels, i.e. 
erythropoietin that stimulates erythropoietic activity has been shown to down-regulate 
liver hepcidin mRNA-expression in mice102. However, in the absence of erythropoietic 
activity, hepcidin expression is no longer suppressed43,103.  
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The strong inverse association between erythropoietic drive and hepcidin production 
was also observed in various patients with congenital chronic anemias104,105, which 
are characterized by low urinary hepcidin levels. 
The influence of these strong regulators, together with the iron store status was 
recently studied in healthy controls and patients with iron metabolism disorders in 
which a relative hepcidin level was calculated applying a simple additive algorithm 
(Kemna et al, submitted). Based on actual measured transferrin saturation levels as 
parameter reflecting the iron store status, sTfR as indicator for erythropoietic activity, 
and C-reactive protein (CRP) for inflammation, the calculated relative hepcidin levels 
showed a strong correlation with the actual measured serum hepcidin levels in these 
patients using the SELDI-TOF MS method (R = 0.756, P < 0.001; results not shown). 
This simplified working model implies that hepcidin is dominantly regulated by these 
three main regulating pathways. These insights enable the construction of an additive 
graphic model that combines the nett effect of the erythropoietic activity and store 
regulation with the hepcidin inducing effect of inflammation in different iron metabolism 
disorders, as displayed in Figure 4 (page 126). 
 
5.2.3 Hepcidin in hereditary hemochromatosis 
Both SELDI-TOF MS and the dotblot method were used to measure hepcidin levels 
in juvenile cases of hemochromatosis, and were found to be extremely low19,66,106,107. 
Less severely decreased, but still clearly inappropriately low urinary hepcidin levels, 
were found in patients with TFR2 mutations using the urine dotblot method108. 
Similarly, decreased mRNA levels were seen in liver biopsies of HFE-KO or deficient 
mice and man109-111, whereas levels ranging to almost normal values in serum and 
urine were found in HFE-hemochromatosis patients19,87. Although, the mechanism 
behind this observed variability in hepcidin values especially in classic 
hemochromatosis is not completely clear yet, the presence of iron overload at 
presentation and that of the increased erythropoiesis upon phlebotomy treatment are 
likely to contribute (B. van Dijk and D.  Swinkels. Unpublished observations).  
In ferroportin disease hepcidin concentrations appear to vary with the sequence 
variations of the gene and the way they influence the activity of the ferroportin 
protein23,112,113. Patients with 162delVal and N144H alterations in ferroportin were 
reported to give high hepcidin levels with a loss in function of ferroportin19,106, 
whereas in cases of other variants with a gain of function the hepcidin levels are 
normal but relatively too low for the degree of iron loading in these patients19,114.  
 
5.2.4 Hepcidin in secondary iron overload 
The dotblot and SELDI-TOF method were exploited to observe inappropriately 
low/normal hepcidin levels for the degree of iron load in thalassemic patients19,104,106, 
which is in concordance with expression levels found in mice115-118 and are thought to 
be the cause of increased iron uptake. Most of these patients are transfusion 
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dependent, thereby aggravating the iron burden. The lower hepcidin levels mostly 
found in thalassemia intermedia compared to major can be attributed to the higher 
degree of erythropoiesis expansion and lower degree of iron burden of the intermedia 
form119. Interestingly, in thalassemia patients it is shown that urinary hepcidin 
concentrations increase in response to transfusions after 3-4 days. This is most likely 
a result of relief of anemia which decreases the bone marrow demand for iron104.  
 
5.2.5 Hepcidin and renal anemia 
SELDI-TOF MS measurement of serum hepcidin in end stage renal disease patients 
showed accumulated hepcidin levels that could be partly reduced by hemodialysis97. 
This accumulation suggests a contribution of hepcidin to the pathogenesis of renal 
anemia. In various kidney diseases, renal anemia occurs. Much of the etiology 
behind this anemia is still unclear, but is thought to be caused by reduced EPO 
production and is therefore mostly treated by administration of human recombinant 
erythropoietin (EPO) in combination with oral iron120. Other factors like 
hyperparathyroidism, aluminum toxicity, systemic inflammation, and impaired iron 
metabolism seem to be of minor importance121. Theoretically, in renal diseases 
hepcidin levels might be increased due to its decreased clearance and low grade 
inflammation described to be associated with end stage renal disease hereby 
decreasing the iron availability, but also might be influenced by concomitant iron 
deficiency122.  
 
5.3 Differential diagnosis and therapeutic implications 
The outcomes of the human studies as described in the previous sections have 
implications for the use of hepcidin as a diagnostic and therapeutic tool. The fact that 
these implications are based on small series, sometimes even on a few cases, shows 
that large scale clinical validation still is needed to prove the power of hepcidin in 
differential diagnosis.  
First, the circadian rhythm observed for serum might necessitate sampling protocols 
for hepcidin analysis that include standardization of time of blood withdrawal, similar 
to that for the assessment of serum iron levels or transferrin saturation.  
Second, recognition of iron deficiency anemia (IDA) in the context of anemia of 
chronic disease (ACD) is currently performed with routine biochemical parameters 
such as, transferrin saturation, ferritin, CRP and less often soluble TfR (sTfR), zinc 
protoporphyrin and new erythrocyte indices which all have their own 
disadvantages77,123-126. In contrast to increased levels of hepcidin in ACD, both in 
vitro iron deficiency15 and classic IDA in man are associated with low hepcidin 
levels19,87 which makes hepcidin a potential marker for detection of IDA in ACD77. 
However, studies in anemic patients suffering from diseases such as rheumatoid 
arthritis, inflammatory bowel diseases, cancer, and end stage renal disease are 
needed to validate the potency of hepcidin measurements under these conditions.  
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Table 1. Hepcidin values in the various pathological conditions of mice and man. 
 
A. Pathological conditions Hepcidin# Human Animal Reference 
Elevated iron stores/ iron overload ↑ U 
mRNA 
 
 
mRNA (mice) 
76,87,96 
69,87 
14,69,78 
     
Iron deficiency/ hypoxia ↓↓ S 
U 
 
 
mRNA (mice) 
19 
19,87,96 
15,102 
     
Increased and/or ineffective erythropoiesis † ↓↓ S 
U 
mRNA 
 
 
 
mRNA (mice) 
19 
19,104,105,106 
44,105 
43,103,115-118 
     
Anemia of chronic disease/ 
inflammation/infection 
↑ / ↑↑ S 
U 
mRNA 
 
 
 
mRNA (mice) 
19,97 
19,78,87,96,101 
87,133 
14,15,55,56,59,78,133 
     
Severe obesitas (BMI > 40 Kg/m2 ) ↑ mRNA  39 
     
Alcohol abuse  ↓ mRNA  
mRNA (rat) 
134 
74,134 
     
Liver disease‡ ↑ / N / ↓ mRNA  127 
 
B.Hereditary 
Hemochromatosis Gene 
OMIM 
type§ Hepcidin
# Human Animal Reference 
       
Classic HFE 1 ↓ S 
U 
mRNA 
 
 
 
mRNA (mice) 
19 
19,96,87 
110 
12,109,111,113 
       
Juvenile       
    HJV-related HJV 2a ↓↓ S 
U 
 
 
mRNA (mice) 
19,107 
19,66,107 
58,129 
   Hepcidin-related HAMP 2b n.d. U  
mRNA (mice) 
106 
12,86 
       
TfR2-related TFR2 3 ↓ U  
mRNA (mice) 
108 
130,131,132 
       
Ferroportin disease       
  “Loss of function”  
           phenotype 
SLC40A1 4 ↑ S 
U 
mRNA 
 19 
19,106 
112,113 
  “Gain of function”  
           phenotype 
SLC40A1 4 N U 
mRNA 
 114 
112,113 
       
 
† After phlebotomy or in iron loading anemia’s. 
‡ Depending on status of inflammation, iron loading or fibrosis stage. 
§ OMIM, Online Mendelian Inheritance in Man.  
# ↓↓, strongly decreased; ↓, mildly decreased; N, normal; ↑, mildly increased; ↑↑, strongly increased. n.d., not detectable. 
U, Urine; S, Serum 
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Third, hepcidin analysis might have a role as a screening, prognostic and monitoring 
test for hereditary hemochromatosis (HH), provided that abnormalities in liver 
functions127, inflammation and a short interval between sample collection and 
phlebotomy are excluded. 
As shown in Table 1, panel B, at presentation urinary hepcidin levels are low of even 
undetectable in all cases of juvenile hemochromatosis and likely to be moderately 
decreased or inappropriately low for the increased iron stores in TfR2 and HFE 
sequence variants. In our opinion assessment of hepcidin values might be 
instrumental to determine the likelihood of candidate genes involved in patients with 
non-HFE HH. This might reduce the workload and costs of the cumbersome 
procedures of screening for sequence variations in the multiple genes responsible for 
hemochromatosis77. Assessment of hepcidin levels or hepcidin/ferritin ratio’s can be 
potentially useful in the prediction of biochemical or clinical penetrance of HFE-
related HH as well as in monitoring of phlebotomy treatment, in which hepcidin levels 
below a certain threshold might become an indication to increase the phlebotomy 
interval.  
Fourth, in iron loading anemias such as thalassemia, studies have suggested 
hepcidin or hepcidin/ferritin index values at the lower end of reference range as a 
result of suppressed hepcidin production due to high and less effective erythropoietic 
activity103. These findings may be relevant in the search for non-invasive measures of 
iron burden and improved therapeutic interventions for these often congenital 
diseases. 
Finally, determination of hepcidin levels might turn out to be of value in the prediction 
of a response to EPO (and iron) treatment in patients with anemia’s of chronic 
disease as well as in the monitoring of EPO treatment. To date, the forecast how 
patients will react on EPO treatment is complicated by the co-existence of several 
factors that contribute to anemia, such as inflammatory activity and liver toxic 
therapy.  
Importantly, additional investigations are warranted to determine hepcidin levels in 
chronic kidney disease, end stage renal disease, upon hemodialysis and EPO and/or 
iron treatment in relation to iron and inflammatory status and blood counts. These 
studies will pave the way for novel diagnostic and more optimized therapeutic 
strategies in patients treated with EPO.  
In conclusion, improved hepcidin assays are expected to increase insight in 
circulating hepcidin levels in various conditions and its kinetics. This knowledge aids 
in the development of hepcidin agonists and antagonists or the targeting of other 
proteins of the hepcidin regulatory circuitry pathways that will then be of value in the 
treatment of these iron related disorders. 
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6. Scope of this thesis 
The major aim of this thesis was the development of a high through-put assay for 
hepcidin in order to study the regulation of this peptide, and to gain knowledge on the 
role of hepcidin in iron metabolism. Chapter 2 presents a novel urinary hepcidin 
assay exploiting surface-enhanced laser desorption/ionization time-of-flight mass 
spectrometry (SELDI-TOF MS). This assay showed to have a strong correlation with 
the only pre-existing antibody-based dotblot assay. As described in chapter 3, further 
analytical improvement of this assay expanded the usability of hepcidin analysis also 
for serum samples and made it possible to determine associations with other iron 
related parameters, especially in patients with distorted iron metabolism. By using 
this serum hepcidin assay chapter 4 shows that insights on hepcidin regulation, 
foremost gained form in vitro cell culture and mice studies, can indeed be translated 
to the human in vivo model. Besides this, chapter 4 also describes an algorithm, 
based on biochemical serum parameters reflecting the main hepcidin regulators, 
which is capable to predict highly accurate the measured serum hepcidin levels.  
Chapter 5, shows a time-course analysis of urinary hepcidin, serum iron and plasma 
cytokine levels in a human endotoxemia experiment that defines the temporal 
associations between Interleukin 6, hepcidin and iron during inflammation. Using this 
endotoxemia model, next to hepcidin the contribution of nitric oxide (NO) in the 
development of hypoferremia was assessed with the use of aminoguanidine as 
specific inducible NO synthase (iNOS) inhibitor during acute inflammation, as 
described in chapter 6. 
Finally, the clinical use of hepcidin in the pre-screening of non-HFE hemochromatosis 
patients is described in chapter 7. These results indicate a potential role for hepcidin 
measurements in clinical practice which has to be explored more intensively in the 
near future. 
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Abstract 
The hepatic peptide hormone hepcidin is the central regulator of iron 
metabolism and mediator of anemia of inflammation. To date, only one specific 
immuno-dot assay to measure hepcidin in urine had been documented. Here 
we report an alternative approach for quantification of hepcidin in urine by 
surface-enhanced laser desorption/ionization time-of-flight mass spectrometry 
(SELDI-TOF MS).  
Peptide peaks were detected corresponding to the 3 forms of hepcidin 
normally found in urine. The identity of the peptide peak equivalent to hepcidin-
25 was confirmed using synthetic human hepcidin-25. 
Validation of our MS data on samples with various hepcidin levels showed a 
strong correlation with previous immuno-dot assay results (Spearman R = 
0.9275, P< .001). Most importantly, this hepcidin assay clearly discriminates 
between relevant clinical iron disorders. 
In conclusion, this novel MS urine hepcidin assay is easy to perform and 
available to a wide audience. This enables the implementation of hepcidin 
measurements in large clinical studies. 
 
Introduction 
Hepcidin is a small, cysteine-rich cationic peptide produced by hepatocytes1-3, 
secreted into plasma and excreted in urine. Hepcidin expression is induced by iron 
stores and inflammation3 and suppressed by hypoxia and anemia5. Hepcidin is 
proposed to be the key regulator of iron metabolism and its discovery has changed 
our understanding of the pathophysiology of iron disorders.  It now appears that 
hepcidin deficiency is the cause of most types of hereditary hemochromatosis and 
that hepcidin excess mediates anemia of inflammation4. Measurements of hepcidin 
concentrations could therefore be useful in diagnosis of iron disorders and would 
provide further insight into hepcidin regulation in vivo. However, assays for hepcidin 
detection and quantification in plasma or urine have not been generally available, and 
the development of reagents has been hampered by technical difficulties6,7. The 
development of immunochemical methods based on the production of specific anti-
hepcidin antibodies is difficult due to the small size of hepcidin (25 amino acids), 
conservation between animal species8 and the limited availability of the antigen as 
the production of synthetic hepcidin in its native conformation9 or the isolation of 
hepcidin from urine2 involves complex, time-consuming procedures. To date, only 
one immunochemical assay was successfully used to quantify urinary hepcidin in 
clinical studies10. 
We sought to develop a more widely available, high-throughput assay. Here we 
report a new quantification method for hepcidin in urine by the use of surface-
enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF 
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MS). This provides a fast assay with increased simplicity and accessibility that 
circumvents the difficulties encountered with antibody and antigen production. 
Moreover, this assay has also the potential to provide insight in the proportional 
contribution of the 3 known hepcidin isoforms that can be found in urine (hepcidin-20, 
-22, and -25). 
 
Study design 
Urine collection and storage 
Approval was obtained from the Radboud University Nijmegen Medical Centre 
institutional review board for these studies. Informed consent was provided in 
accordance with the Declaration of Helsinki. From healthy volunteers second-
morning urine was collected. Clinical urine samples from patients in the intensive 
care unit with severe sepsis (selection by protocol and APACHE [Acute Physiology 
and Chronic Health Evaluation] score) were collected by urine catheter. Samples 
from patients with (1) secondary iron overload (myelodysplasia [MDS]; World Health 
Organization [WHO] classification of refractory anemia [RA] or RA with ring 
sideroblasts [RARS] with blood-transfusion dependency), (2) iron-deficient anemia 
(hemoglobin level <7.5 mM and mean corpuscular volume [MCV] <85 fl), and (3) 
hereditary hemochromatosis (homozygous C282Y, in various stages of phlebotomy 
treatment, urine samples at least 1 week after the last phlebotomy) were collected 
during visits at the outpatient department of the Radboud University Nijmegen 
Medical Center, The Netherlands. Healthy volunteers and outpatients lacked clinical 
signs of inflammation. Freshly collected urine was centrifuged for 10 minutes at 
2600g, and the supernatant was divided in aliquots and stored at – 20°C. Patient 
laboratory characteristics are shown in Table 1. 
 
Table 1. Laboratory characteristics of patients and healthy volunteers who provided urine 
samples for the clinical validation  
 
 Hemoglobin, nM MCV, fL Serum iron (Fe), µM Fe/TIBC (TS), % Ferritin, µg/L CRP, mg/L 
Normal, n=7 8.1 (7.8-9.1) n.a. 20 (14-29) 32.8 (24.6-52.7) 80 (32-190) <5 (<5-8) 
Sec. Iron overload, n=8 5.6 (3.4-6.2) n.a. 39 (29-63) 96.0 (77.1-100.0) 3088 (568-14 496) <5 (<5-<5) 
HH, n=7 8.7 (7.2-9.6) n.a. 27 (9-39) 50.9 (16.1-93.5) 54 (12-2118) <5 (<5-<5) 
Iron def. Anemia, n=6 7.1 (3.3-7.4) 78 (69-84) 10 (2-11) 16.0 (2.4-19.6) 6 (2-11) <5 (<5-6) 
Endotoxemia model, n=6 8.1 (7.2-9.1) n.a. 16 (4-22) 25.6 (8.0-38.6) 65 (15-219) 8 (5-33) 
Sepsis, n=4 5.4 (4.9-6.2) n.a. 1 (1-4) 7.1(3.8-17.4) 370 (280-505) 192 (124-227)
Data are expressed as the median with the range in parentheses. 
HH indicates hereditary hemochromatosis; n.a., not analyzed; CRP, C-reactive protein; and TIBC, total 
iron binding capacity. 
 
  37
  
Urine hepcidin assay  by SELDI-TOF MS 
Protein chip preparation and SELDI-TOF MS measurements  
The preparation procedure was based on protocols from Ciphergen and previous 
reports11,12. 8-spot hydrophilic Normal Phase chips (ProteinChip NP20; Ciphergen 
Biosystems, Fremont, CA), mimicking normal-phase chromatography with silicate 
functionality were used for their binding characteristics of proteins through hydrophilic 
and charged residues.  
Urine samples were thawed, vortexed, and centrifuged for 10 minutes at 2600g. 
Urine supernatant (7 µl) was applied to the chip and incubated for 30 minutes in a 
humidity chamber. When protein overload was expected, a reduced sample volume 
was applied (minimum 1 µl). Spots were washed 3 times with 10 µl ultraPURE 
distilled water (Invitrogen, Breda, The Netherlands) and air-dried for 10 minutes. 
Finally, 0.8 µl of a saturated solution of sinapinic acid in 0.5% (vol/vol) trifluoroacetic 
acid and 50% (vol/vol) acetonitrile, used as energy-absorbing matrix (EAM), was 
applied to each spot surface, allowed to air-dry, and reapplied. Mass spectrometry 
was performed with a PBS IIc mass spectrometer (Ciphergen Biosystems).  
Data were collected using the following settings: 2 warming shots at laser intensity 
185 (not collected); collection of 50 shots at laser intensity 180 every 5 positions 
between 29 and 89; high mass 50 000 Da; detector voltage 2900V; detector 
sensitivity 9. The acquired mass range was from a mass-over-charge (m/z) ratio of 
1500 to 10 000. External mass calibration was performed with synthetic human 
hepcidin (Peptides International, Louisville, KY). The bioactivity of this synthetic 
peptide was shown to be comparable to the synthetic hepcidin-25 used in the 
immuno-dot assay13. The mass of the synthetic hepcidin-25 from Peptides 
International was verified by matrix-assisted laser desorption/ionization (MALDI)-TOF 
MS (2787.80 m/z) and corresponded well with data from the supplier (2789 m/z), and 
previous reported values (2789 m/z) for hepcidin-252. Peak annotation was 
performed with Ciphergen ProteinChip Software (version 3.2.0), after baseline 
subtraction and adjustment (fitting 8 times expected peak width). Peak intensity 
levels were normalized to urinary creatinine values and reported as Mega 
intensity/mmol creatinine. We found that changes in solvent and matrix (e.g. sample 
dilution) can influence the flight behavior of peptides during SELDI-TOF MS 
analysis11. Therefore, we aimed at a semiquantitative method for hepcidin 
quantification in urine. 
 
Statistic analysis 
Analyses were performed with GraphPad Prism software (version 4.0; GraphPad 
Software, Inc, San Diego, CA). Correlation was tested by Spearman rank test. Group 
differences were tested for statistical significance by paired t test and Mann-Whitney 
U test. 
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Results and discussion 
Hepcidin tracing by mass spectrometry 
To investigate the feasibility of a mass spectrometry-based assay for the 
quantification of urine hepcidin, a pilot SELDI-TOF MS was conducted where the 
spectra of a patient with septicemia and a healthy volunteer were generated. Figure 
1A I-II, shows in both spectra a clear peak at 2788 m/z that corresponds with the 
peak mass of 2789 m/z from the synthetic human hepcidin-25 peptide (Figure 1A III).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Urine 
hepcidin profiles by 
SELDI-TOF MS, and 
urine hepcidin levels in 
different iron 
metabolism disorders. 
(A) SELDI-TOF MS 
spectra from urine 
samples of a septicemia 
patient (I), healthy 
subject (II), and human 
synthetic hepcidin-25 
(III). Urine hepcidin-25 
peaks from spectra 
shown in panel I and 
panel II correlate with the 
reference human 
synthetic peptide 
(spectrum shown in 
panel III). The annotated 
peak masses correspond 
with hepcidin-20, -22, 
and -25.2 (B) Urinary 
hepcidin excretion in 
patients with transfusion-
induced iron overload 
(□), treated hereditary 
sis (▲), 
iron deficiency anemia 
(¯), endotoxemia after 
LPS injection(Â), and 
sepsis (○) compared with 
healthy subjects  (¡). In 
each group the median 
is indicated. 
hemochromato
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Besides hepcidin-25, the urine spectra also show peaks that correspond with 
reported masses of the N-terminally truncated hepcidin-20 and -22 (respectively 2192 
and 2436 m/z, as measured by MALDI-TOF MS)2. As expected, the intensities of the 
hepcidin peaks are strongly increased (about 3-fold) in the case of septicemia (Figure 
1A I-II).  
The results indicated hepcidin was detectable and quantifiable in urine samples by 
SELDI-TOF MS As the lack of commercially available peptides hampers the mass 
confirmation of the 20- and 22- amino-acid hepcidin forms, measurements will be 
based on the hepcidin-25 peptide until new insights on the 20- and 22- amino-acid 
peptides will approve a change in the data analysis protocol. 
 
Validation of SELDI-TOF MS measurements  
To validate SELDI-TOF MS measurements, we performed SELDI-TOF MS on urine 
samples from our previous study14, in which hepcidin concentration was determined 
by the immuno-dot assay. The samples were from 10 volunteers injected with LPS 
who collected urine at 4 time points within a 22-hour time frame14. Statistic analysis 
showed a strong significant correlation between the two methods (Spearman 
R=0.9275, P< .001) and no significant differences between methods for each 
volunteer at each time point (Paired t test P> .05). These results prove that SELDI-
TOF MS approach for urinary hepcidin measurements is comparable to the published 
immuno-assay method.  In addition to providing accurate results, the assay is fast, 
simple and high-throughput, and therefore suitable for large experimental clinical 
studies. 
 
Implementation in Clinical Practice 
To investigate whether hepcidin quantification by mass spectrometry can distinguish 
between different clinical iron metabolism disorders, urine from patients with several 
iron-related diseases were used for SELDI-TOF MS measurements. Figure 1B shows 
that patients suffering from septicemia as well as those injected with LPS had 
significant elevated urinary hepcidin excretion compared with healthy subjects 
(Mann-Whitney U test, P< .05). Patients with iron deficiency anemia, and (partly) 
compensated hereditary hemochromatosis showed significant reduced hepcidin 
excretion compared with healthy subjects (P< .05). Patients with MDS with 
transfusion-induced iron overload, serum transferrin saturation values higher than 
77%, and ferritin levels over 500 µg/L showed relatively increased but greatly varying 
hepcidin levels. This variety precludes differentiation of patients with secondary iron 
overload from healthy individuals (P= .054), while median difference with acute 
infection patients is still significant (P< .05). These results are consistent with 
previous reports on hepcidin levels in physiologic and pathophysiologic states10,15-17. 
In addition, the SELDI-TOF MS method would be suitable for differentiation between 
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(hepcidin induced) anemia of inflammation, and iron deficiency anemia where 
hepcidin excretion is physiologically reduced. 
In conclusion, we present a novel mass spectrometry-based assay for the high-
throughput measurement of hepcidin levels in urine. We anticipate that this will 
become an important tool to increase our insight in the role of hepcidin in iron 
metabolism-related disorders. 
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Urine  and Serum Hepcidin Measurements by MS 
Abstract 
Discovery of the central role of hepcidin in body iron regulation has shed new 
light on the pathophysiology of iron disorders. Information is lacking on newer 
analytical approaches to measure hepcidin in serum and urine. Recent reports 
on measurement of urine and serum hepcidin by surface-enhanced laser-
desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) 
necessitate analytical and clinical evaluation of MS-based methodologies.  
We used SELDI-TOF MS, Immunocapture, and tandem MS to identify and 
characterize hepcidin in serum and urine. In addition to diagnostic application, 
we investigated analytical reproducibility and biological and preanalytical 
variation for both serum and urine on Normal Phase 20 and Immobilized Metal 
Affinity Capture 30 ProteinChip arrays. We obtained samples from healthy 
controls and patients with documented iron-deficiency anemia, inflammation-
induced anemia, thalassemia major, and hereditary hemochromatosis. 
Proteomic techniques showed that hepcidin-20, -22, and -25 isoforms are 
present in urine. Hepcidin-25 in serum had the same amino-acid sequence as 
hepcidin-25 in urine, whereas hepcidin-22 was not detected in serum. The 
interarray CV was 15% to 27%, and interspot CV was 11% to 13%. Preliminary 
studies showed that hepcidin-25 differentiated disorders of iron metabolism. 
Urine hepcidin is more affected by multiple freeze-thaw cycles and storage 
conditions, but less influenced by diurnal variation, than is serum hepcidin.  
SELDI-TOF MS can be used to measure hepcidin in both serum and urine, but 
serum requires a standardized sampling protocol.  
 
Introduction 
The iron-regulating peptide hepcidin is produced by hepatocytes and secreted into 
plasma1-3. Increased iron stores and inflammation induce hepcidin expression3, 
whereas suppression occurs during hypoxia and anemia4. Although recognition of the 
central role of hepcidin in body iron regulation has increased our understanding of the 
pathophysiology of iron disorders5,6, few investigative tools are available; these include 
an immunodot method for measuring urinary hepcidin7 and a urinary hepcidin assay 
based on surface-enhanced laser-desorption/ionization time-of-flight mass 
spectrometry (SELDI-TOF MS) for differentiating various disorders of iron 
metabolism8. A SELDI-TOF MS-based serum assay is under development for 
measuring hepcidin in serum9, but this method requires optimization and evaluation to 
facilitate clinical investigation of hepcidin measurement in serum compared with urine 
and the biological variation of hepcidin in body fluids. In this study, we used SELDI-
TOF MS, Immunocapture, and tandem MS to identify and characterize hepcidin in 
serum and urine. 
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Material and Methods 
Study participants 
Study participants included a control population of healthy volunteers (laboratory 
personnel), hereditary hemochromatosis (HFE C282Y homozygous) patients cross-
sectionally selected from a family screening program (various stages of phlebotomy 
treatment), iron deficiency anemia patients (Hb ≤8.3 mmol/L men, ≤7.3 mmol/L 
women; mean corpuscular volume ≤80 fl; ferritin ≤10 µg/L), and thalassemia major 
patients treated with chelation therapy. The patients were recruited by their 
physicians during outpatient clinic visits (all in Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands, except for the thalassemia major patients, who 
were in Ospedale Sant’Eugenio, Rome, Italy). Endotoxemia samples from volunteers 
injected with lipopolysaccharide were selected from a human endotoxemia project10. 
Written informed consent was obtained from all study participants, according to the 
Declaration of Helsinki. Characteristics of the study participants are shown in Table 
1.  
 
Table 1. Characteristics of subjects who provided sample material for assay validation 
 
 Control 
 
n = 20 
Endotoxemia 
Model 
n = 28 
Iron deficiency  
anemia 
n = 6 
Thalassemia 
Major 
n = 5 
Hereditary 
hemochromatosis
n = 14 
Hemoglobin (mmol/L) 8.7 (7.8 – 11.0) n.a. 6.7 (5.0 – 8.3) 6.3 (6.1 – 7.3) 9.3 (7.5 – 12.0) 
MCV (fL) 88 (84 – 93) n.a. 77 (76 – 79) 86 (78 – 88) 90 (83 – 95) 
Serum iron (Fe) (µmol/L) 19 (9 – 38) 18 (7 – 38) 6 (4 – 7) 52 (47 – 62) 22 (10 – 48) 
Fe/TIBC (TS) (%) 35 (14 – 73) 40 (23 – 79) 8 (5 – 10) 98 (93 – 100) 56 (21 – 100) 
Ferritin (µg/L) 60 (11 – 191) 120 (31 – 233) 6 (6 – 10) 784 (272 – 1710) 64 (28 – 1361) 
CRP (mg/L) < 5 9 (< 5 – 33) < 5 < 5 < 5 
U Hepc-25 (NP20)  
(M Int/mmol Cr) 
0.52 (0.09 – 2.97) 6.16 (1.27 – 19.78) 0.01 (0.01 – 0.02) 0.21 (0.04 – 0.98) 0.15 (0.02 – 1.25)
U Hepc-25 (IMAC30) 
(M Int/mmol Cr) 
1.45 (0.52 – 7.83) 12.97 (1.95 – 30.81) 0.10 (0.01 – 0.19) 0.59 ( 0.24 – 2.96) 0.66 ( 0.08 – 4.50)
S Hepc-25 (IMAC30) 
(M Int/L) 
4.38 (0.58 – 9.95) 12.69 (4.11 – 27.33) 0.41 (0.35 – 0.60) 0.28 (0.18 – 2.42) 1.60 (0.19 – 9.39)
 
Data are expressed as the median with range in parentheses. 
n.a. indicates not analyzed; CRP, C-reactive protein; TIBC, Total iron binding capacity; U Hepc-25, urinary  
hepcidin-25; S Hepc-25, serum hepcidin-25; M Int/mmol Cr, Mega Intensity/mmol creatinine. 
 
In addition, collaborators from several medical centers in The Netherlands provided 
urine and serum samples from 3 patients with distinct forms of hereditary 
hemochromatosis not associated with the hemochromatosis (HFE) gene [Online 
Mendelian Inheritance in Man (OMIM) type 2a, homozygous G320V HJV mutation11; 
OMIM type 4, N144H-caused ferroportin disease12]. Characteristics of these patients 
are shown in Table 2. 
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Table 2. Urinary and serum hepcidin-25 levels in types of non-HFE hereditary hemochromatosis. 
 
 
 Reference 
values 
FPN N144H HJV G320V (1) HJV G320V (2) 
Gender m / f m m m 
Hemoglobin, mmol/L 8.1 – 10.7 n.a 8.3 8.7 
MCV, fL 80 – 98 n.a 89 94 
Serum iron (FE), µmol/L 10 – 25 17 47 53 
Fe/TIBC (TS), % 30 – 60 26.6 78.3 96.4 
Ferritin, µg/L 15 – 280 68* 60* 187* 
CRP, mg/L < 10 < 5 < 5 < 5 
U Hepc-25 (NP20 array), M Int/mmol creatinine 0.09 – 2.97 4.56 0.01 0.01 
U Hepc-25 (IMAC30 array), M Int/mmol 
creatinine 
0.52 – 7.83 5.19 0.01 0.06 
S Hepc-25 (IMAC30 array), M Int/L 0.58 – 9.95 10.09 0.58 0.40 
n.a indicates not available; * phlebotomized values 
 
We collected samples randomly between December 2005 and June 2006, at no 
specified time of day, except from the endotoxemia patients, from whom samples 
were collected according to a tight time schedule10,13. Urine and blood samples were 
centrifuged immediately after collection, divided into aliquots to avoid multiple freeze-
thaw cycles, and stored at -80°C. We performed the hepcidin assay within 2 months 
after collection. 
 
Laboratory measurements 
Using an Abbott Aeroset analyzer, we measured total serum iron and latent iron 
binding capacity by the ascorbate/FerroZine colorimetric method, urine creatinine by 
enzymatic/colorimetric detection (Roche Diagnostics), and C-reactive protein by 
immunologic agglutination detection with latex-coupled polyclonal anti-C-reactive 
protein antibodies (Abbott Laboratories). We quantified serum ferritin by a solid-
phase, 2-site chemiluminescent immunometric assay (Immulite 2000 and 2500, 
Diagnostic Products Corp.) and routine hematology characteristics by use of a 
Sysmex XE-2100 analyzer. 
 
SELDI-TOF MS  
We performed nonblinded hepcidin measurements by use of SELDI-TOF MS as 
previously reported8. In brief, a 5-µL sample was applied to Immobilized Metal Affinity 
Capture 30 (IMAC30), Normal Phase 20 (NP20), or cation exchange ProteinChip 
arrays (CM10), all equilibrated with appropriate buffers according to the 
manufacturer’s instructions (Ciphergen Biosystems). Loaded arrays were incubated 
in a humidity chamber for 30 min and then washed according to the manufacturer’s 
instructions and air-dried for at least 15 min. Finally, 1 µL of energy-absorbing matrix 
(EAM), made up of a 12.5 g/L solution of sinapinic acid in 500 mL/L acetonitrile 
(ACN) containing 5 mL/L trifluoroacetic acid (TFA), was applied twice onto each spot 
surface with the use of polymer-free polypropylene pipette tips and allowed to air dry 
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for 5 min. Mass-to-charge (m/z) spectra were generated using a Ciphergen Protein 
Biology System IIc TOF mass spectrometer at laser intensity 180 (NP20 and CM10) 
or 175 (IMAC30); detector sensitivity 9; high mass to acquire 50 kDa; optimization 
interval 1500 to 10 000 Da. External mass calibration was performed with a mixture 
of synthetic human hepcidin-25 peptide (2789.4 Da, Peptides International), hepcidin-
22, and hepcidin-20 (2436.1 Da and 2191.8 Da, respectively; kindly provided by E. 
Nemeth, University of California, Los Angeles). Peak annotation was performed with 
Ciphergen ProteinChip Software version 3.2.0. From unpublished experiments we 
found that for serum and urine, normalization to total ion current (TIC) did not 
improve the hepcidin measurements and was therefore not applied in this study. 
Urine hepcidin measurements showed a relationship with TIC and total peptide 
content, which was predominated by hepcidin under the applied experimental 
conditions and instrumental settings (data not shown). Consequently, normalization 
of urine hepcidin values to TIC leads to loss of differentiation between samples. In 
contrast, due to the relatively stable protein content of serum samples, the serum 
hepcidin concentrations did not significantly change upon normalization to TIC 
(unpublished observations). Although the reabsorption and excretion characteristics 
of hepcidin are unclear, we used urinary creatinine to normalize all peak intensities 
for hepcidin-25 in urine. Normalization on creatinine is a prerequisite for comparison 
of urine hepcidin measurements because it is the best method to correct for the 
highly fluctuating concentration differences between urine samples. Relative 
concentrations were expressed as mega-intensity units per millimole of creatinine. 
Relative concentrations of serum hepcidin-25 were expressed as mega-intensity 
units per liter. Information on the assay can be found on: www.UMCN.NL/Hepcidin. 
 
Purification of peptides from serum and urine  
We first fractionated serum samples by use of spin columns containing Q HyperD F 
resin (Pall Corp.), eluted the flow-through fraction by centrifugation, and eluted bound 
proteins with buffers of pH 9, 7, 5, 4, and 3. We analyzed fractions by use of IMAC30 
arrays. Every serum fraction or urine sample was adjusted to final concentrations of 
5% ACN and 0.5% TFA and bound to PLRP-S beads (Polymer Laboratories Varian). 
Bound proteins were eluted with 5%, 10%, 20%, 30%, 40%, 50%, and 60% ACN 
solutions containing 0.1% TFA. We detected proteins in eluted fractions by profiling 1 
µL of each fraction on an NP20 array using Protein Biology System IIc MS.  
 
Identification of peptides by tandem mass spectrometry 
We analyzed peptides of interest for a presence of disulfide bonds. Aliquots of 30% 
ACN fractions were air-dried on an NP20 array. Solution containing 10 mmol/L 
dithiothreitol (DTT) in 50 mmol/L ammonium bicarbonate, and the sample loaded 
arrays, was preheated to 70°C. Then we loaded 10-µL aliquots of the DTT solution 
onto the spots and air-dried them at 70°C. After complete evaporation of solutions and 
cooling to room temperature, we applied EAM. We acquired single MS spectra for 
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unreduced and DTT-reduced samples by use of a Q-STARXL tandem mass 
spectrometer (MS/MS; Applied Biosystems) equipped with a Ciphergen PCI-1000 
ProteinChip Interface. We used the reduced samples to acquire MS/MS spectra. We 
subjected the ions of interest (m/z values of 2198 for hepcidin-20, 2442 for hepcidin-
22, and 2796 for hepcidin-25) to collision-induced dissociation and submitted the 
results to the database-mining tool Mascot (Matrix Science) for peptide identification. 
 
Immunocapture 
We captured hepcidin from urinary samples by use of Protein G coupled to IDM 
beads (Ciphergen Biosystems) and polyclonal rabbit antihepcidin serum (generous 
gift from E. Nemeth and T. Ganz, University of California, Los Angeles). We 
performed all incubation steps at room temperature. Protein G beads were first 
incubated with rabbit antiserum diluted 20 times in 0.01 mol/L phosphate-buffered 
saline (PBS; Sigma-Aldrich Chemie BV) supplemented with 0.1% Triton-X100 (PBS-
Tx). We washed the beads 3 times with PBS-Tx to remove unbound serum proteins 
and resuspended the beads in urine, diluted 20 times in PBS containing a final 
concentration of 0.25 mol/L NaCl and 0.1% Triton-X100 (PBS0.25-Tx). We washed the 
beads 6 times with PBS0.25-Tx to remove unbound and nonspecifically bound 
proteins. Finally, we eluted bound proteins with 500 mL/L ACN containing 3 mL/L 
TFA. To obtain profiles of Protein G-captured proteins, we applied eluates to a CM10 
array equilibrated with 0.1 mol/L ammonium acetate (pH3) and incubated them for 30 
min in a humidity chamber. To obtain reference spectra, we diluted untreated urine 
samples once in equilibration buffer before on-spot incubation. Spots were washed, 
allowed to air-dry, and followed by sinapinic acid application.  
 
Analytical assay characteristics 
We performed spot-to-spot precision for hepcidin-25 on NP20 and IMAC30 
ProteinChip array with 2 human urine samples with medium and high hepcidin 
concentrations. Both samples were applied onto the first 6 positions of the 8-spot 
array, followed by addition of the EAM.  The last 2 spots were used for control 
samples. For serum we followed the same procedure for a single sample. 
We used the same urine and serum samples for a chip-to-chip reproducibility study. 
We collected single measurements for serum and urine on NP20 and IMAC30 array 
types from randomized chip positions for 10 days (8 days for serum application on 
NP20 arrays). Every day a new sample aliquot was thawed, and freshly prepared EAM 
was applied. From these data, we calculated means, SDs, and CVs. 
We measured linearity of peak intensities by dilution of the urine and serum samples 
used for the reproducibility tests with human urine or serum (dilution samples) from a 
patient with hepcidin concentrations below those detectable by SELDI-TOF MS. 
Immediately before sample application, we diluted 1 to 18 µL of sample in a 
polypropylene microcentrifuge container to a 20 µL end volume with the dilution 
sample. After pipette mixing, 5 µL of the diluted sample was spotted on the array. 
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We created standard curves of synthetic hepcidin-25 for both serum and urine 
applications. After dissolving the lyophilized peptide in distilled water (100 µmol/L), the 
peptide was diluted 4500-fold with dilution sample for serum or urine (22.2 nmol/L). 
Dilutions of 18, 16, 12, 8, 4, 2, and 1 µL of the 22.2 nmol/L solution with the dilution 
sample to the final volume of 20 µL yielded a standard curve ranging from 22.2 to 1.11 
nmol/L.   
 
Preanalytical and biological interferences 
We evaluated the influence of multiple freeze-thaw cycles for both serum and urine 
using IMAC30 arrays. Five sera and 4 urine samples from different participants and 
different intensity concentrations underwent 4 freeze-thaw cycles. After every cycle, 
we analyzed hepcidin batchwise by single measurement. 
We studied the existence of a circadian rhythm for hepcidin in serum and urine by 
performing a 24-h time-course in 3 healthy volunteers (1 man, 2 women). Blood and 
urine was collected every 3 h for analysis of routine iron measurements and serum 
and urine hepcidin (IMAC30 array), starting at 6:00 AM with fasting blood and urine 
samples, after which the fasting state was ended. All samples were processed as 
described above and stored at -80°C before analysis (batchwise by single 
measurement). 
  
Statistic analysis 
We performed statistical analyses with GraphPad Prism software, version 4.0. 
Pearson correlation was used for comparison studies. P values < .05 were considered 
significant.  
 
Results  
Hepcidin identification and characterization 
The presence of hepcidin-25 in a human urine8 and serum9 has been demonstrated. 
Our current investigation revealed that, in addition to hepcidin-25, hepcidin-20 can be 
verified in both urine and serum with the use of a purified synthetic reference human 
hepcidin peptide, whereas hepcidin-22 can be identified only in urine (Figure 1A). This 
supports the hypothesis that both the 20- and 25-amino acid peptides are secreted in 
the circulation after production in hepatocytes, whereas the 22-amino acid peptide 
merely is a urinary degradation product of hepcidin-2514.  
In addition to mass tracing, we investigated immunocapture of all 3 known forms of 
hepcidin from urine. Immunoaffinity assays using polyclonal rabbit antihepcidin 
antibodies [the same as those used in hepcidin dotblot assay7] showed that the 3 
peaks annotated as hepcidin-25, -22, and -20 can be specifically captured from a 
human urine sample of a healthy individual (Figure 1B).  
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Figure 1. Hepcidin identification 
and characterization. 
(A), SELDI-TOF MS profiles in 
serum and corresponding urine 
samples from a participant with an 
inflammation response after 
lipopolysaccharide injection. The 
annotated peak masses matched to 
the masses in the reference peptide 
mix that contained purified synthetic 
human hepcidin-20, -22 (E. 
Nemeth, University of California, 
Los Angeles) and -25 (Peptides 
International). (B), Immunocapture 
of urine hepcidin. Urine samples 
from a healthy individual were 
incubated with Protein G beads, 
loaded with either a polyclonal 
antihepcidin rabbit antibody or 
control rabbit IgG. Immunocaptured 
proteins were analyzed by SELDI-
TOF MS, and protein profiles were 
compared with the protein profile of 
an untreated urine sample (upper 
panel). Peaks corresponding to 3 
forms of urine hepcidin8, and those 
corresponding to rabbit IgGs are 
indicated. A peak with m/z 2436 that 
is present in untreated urine, but not 
present in the captured fractions is 
marked (“*”), as it shows that the 
capture of the three hepcidin forms 
was specific.  Notably, on-spot 
incubation of the same urine sample 
with antihepcidin antibodies bound 
to Protein G-loaded arrays, did not 
yield detectable hepcidin 
concentrations (our unpublished 
observations). 
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Figure 2. Hepcidin identification by tandem MS. 
(A): Mascot search results of MS/MS data for DTT-reduced human urinary samples. The ions with m/z 
of 2796, 2442, and 2198 were identified as human hepcidin-25, -22, and -20, respectively. Identical 
result was obtained for the ion with m/z of 2796 from reduced human serum sample (not shown). (B): 
Single MS profile of human urine sample before and after reduction with DTT. A mass shift of 8 Da 
indicates the reduction of 4 disulfide bonds. (C): Aligned MS/MS spectra for the ions with m/z of 2796 
from human serum and urine indicate that both parent ions correspond to the same peptide hepcidin-
25.  
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MS/MS analysis of peptides in a urine sample from an endotoxemia patient confirmed 
that the peaks with m/z of 2198, 2442 and 2796 corresponded to hepcidin-20, -22, and 
-25, respectively (Figure 2A). Similarly, we identified the m/z 2796 peak in serum as 
hepcidin-25. Notably, single MS spectra of urine and serum samples displayed a mass 
shift of +8 Da for all hepcidin forms after reduction with DTT, as exemplified for urine 
hepcidin-25 (Figure 2B). This observation confirms the presence of 4 disulfide bonds 
in these peptides which is a typical characteristic of hepcidin15. Finally, the MS/MS 
spectra for serum and urine peptides with m/z of 2796 displayed mostly the same 
fragment ions, strongly suggesting that both parent ions corresponded to the same 
peptide hepcidin-25 (Figure 2C).  
 
 
Analysis of hepcidin-25 on NP20 and IMAC30 ProteinChip arrays  
Because the biological roles of hepcidin-20, and -22 in iron metabolism are still 
unclear2,14, hepcidin-25 is used for optimization of serum and urine hepcidin 
measurements. To evaluate the ProteinChip array type on the performance of the 
hepcidin-25 assay, we analyzed 73 urine and serum sample pairs from controls and 
patients with various iron metabolism disorders using the previously reported NP20 
and IMAC30 arrays8,9. Although hepcidin concentrations measured using NP20 
arrays are lower than those measured with IMAC30 arrays, both arrays correlate for 
the urinary application (R = 0.928, P < .001; Pearson correlation; Figure 3A). 
Sensitivity was higher with the use of IMAC30 compared to NP20 arrays, likely 
because of highly specific binding of hepcidin to the IMAC-Cu surface. In contrast to 
the IMAC30 arrays, NP20 arrays did not bind detectable concentrations of serum 
hepcidin-25; therefore, we could not perform correlation analyses for serum and urine 
on NP20 arrays.  In contrast, IMAC30 arrays showed a significant correlation (R = 
0.822, P <.001; Pearson correlation; Figure 3B).  
Chip-to-chip variation of the urine application for IMAC30 ranged from 22% at a high 
intensity of 48 to 27.5% at a lower intensity of 20 (Table 3), whereas NP20 variation 
reached 34% for the same samples. Precision was also better for urine hepcidin 
measurements using the IMAC30 chip (CVs 11% and 13%) compared with the NP20 
chip (CVs of 16% and 23%) (Table 3). 
For serum, the reproducibility was strongly affected by differences in protein binding 
capacity of both arrays. Intensities measured from the same sample differed, from an 
intensity of 5 with relatively high CVs on NP20 array to an intensity of 50 with low 
CVs on IMAC30 array. 
We checked the linearity of the urinary and serum hepcidin application on IMAC30 
array by measuring dilution series of urine and serum samples from an inflammation 
patient (single measurements). Figures 4A and B show a high degree of linearity for 
both urine and serum (R = 0.993 and 0.971, respectively). Intensity values >55 seem 
to deviate from linearity, perhaps because of MS detector saturation. Therefore, an 
intensity value of 55 was considered to be the upper level of detection. 
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Figure 3. Detection of serum and urine hepcidin-25 on NP20 and IMAC30 arrays. 
Correlation of urinary hepcidin-25 values as measured by NP20 and IMAC30 ProteinChip arrays (A), 
and  coupled serum and urine hepcidin-25 concentrations measured on IMAC30 array (B). The solid 
line represents the regression line, and the dotted line indicates the 95% CI of the regression line. It 
should be noted that the apparent increased scatter in absolute variation on high hepcidin values 
compared to low values, as presented in panel A of this figure, is because absolute concentrations 
are used in this plot. Relative average for the high values is not more scattered than the low-end 
values (data not shown), which is in concordance with the CV values shown in Table 3. As it is 
currently unknown whether and how much hepcidin is reabsorbed in the tubulus, we cannot indicate 
whether this aspect contributes to the scatter in panel B of this figure. 
 
Table 3. Reproducibility of hepcidin-25 analysis by SELDI-TOF MS in NP20 and IMAC30 chip 
arrays in both serum and urine. 
 
Urine application NP20 IMAC30 
Chip-to-chip*  m/z Intensity m/z Intensity 
Mean 2788.48 13.10 2788.65 19.84 
SD 0.94 4.37 1.96 5.46 
Level I  
CV (%) 0.03 33.4 0.07 27.5 
Mean 2788.37 41.55 2788.45 47.84 
SD 0.89 10.00 1.64 10.50 
Level II  
CV (%) 0.03 24.1 0.06 22.0 
Spot-to-spot**  m/z Intensity m/z Intensity 
Mean 2787.13 15.23 2788.53 17.83 
SD 1.00 2.62 1.55 1.97 
Level I 
CV (%) 0.04 16.5 0.06 11.0 
Mean 2787.88 40.61 2788.24 40.89 
SD 0.53 9.47 1.00 5.25 
Level II 
CV (%) 0.02 23.3 0.04 12.8 
*  Ten-day single measurement with randomized chip position. 
** One chip (6 replicates). 
Serum application NP20 IMAC30 
Chip-to-chip*  m/z Intensity m/z Intensity 
Mean 2788.40 5.26 2788.02 51.96 
SD 1.41 1.73 1.56 7.76 
Level I  
CV (%) 0.05 32.9 0.06 14.9 
Spot-to-spot**  m/z Intensity m/z Intensity 
Mean 2787.54 4.27 2788.33 43.89 
SD 0.60 1.14 0.59 5.06 
Level I 
CV (%) 0.02 26.6 0.02 11.5 
*  Eight-day single measurement (NP20 array) and 10 days single measurement (IMAC30 array) with randomized 
chip position. 
** One chip (6 replicates). 
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The construction of a calibration curve with synthetic human hepcidin-25 showed that 
both NP20 as IMAC30 arrays are capable of producing a 6-point calibration curve 
based on urine matrix (Figure 4C and D). Again, intensity values >55 deviated from 
linearity and therefore were considered as exceeding the upper level of detection. 
Construction of the same concentration interval on IMAC30 array in a serum matrix 
showed hepcidin-25 only for a concentration of 22.2 nmol/L and above (results not 
shown).  
  
 
Figure 4. Linearity study of human hepcidin-25 in urine samples. 
Dilution curve of human urinary inflammation sample (A), and human serum sample (B) on IMAC30 
array.  
Calibration curve of human synthetic hepcidin-25 in urine samples on NP20 array (C), and IMAC30 
array (D). The dotted line indicates upper limit of accurate detection (intensity level of 55). Values 
above this level were excluded from analysis and are shown as open circles (|). 
 
 
Diagnostic application 
We categorized urine and serum sample pairs into 5 groups after clinical diagnosis. 
Figure 5 shows that, despite the variation within each group and a slight overlap, 
differentiation between inflammation-induced and iron deficiency anemia is clear for 
both serum and urine hepcidin concentrations measured on IMAC30 array. The 
results are comparable with the results obtained with NP20 and consistent with 
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previous reports7,8. The broad ranges of the thalassemia group and the 
hemochromatosis group are in accordance with the individual heterogeneity in 
genetic makeup, extent of anemia, and treatment16-18. 
 
Figure 5. Urinary and serum hepcidin-
25 concentrations in selected clinical 
populations. 
Urinary hepcidin-25 concentrations 
measured on NP20 array (A), and 
IMAC30 array (B), and  serum hepcidin-
25 measured on IMAC30 array (C). LPS, 
volunteers injected with LPS (6 h after 
injection); IDA, iron deficiency anemia 
patients; TM, thalassemia major patients; 
HH(YY), C282Y homozygous 
hemochromatosis patients. Box plots 
show 25th and 75th percentile with median 
for every group. Error bars represent 
minimum and maximum values. 
Characteristics of each population are 
shown in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this study we found serum and urine hepcidin concentrations close to zero in 2 
brothers treated for juvenile hemochromatosis (OMIM type 2a), and values in the 
upper level of the reference range for a patient treated for ferroportin disease (OMIM 
type 4; Table 2). These data confirm the potential of hepcidin analysis in 
prescreening for the presence of non-HFE Hemochromatosis.   
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Preanalytical and biological determinants that influence hepcidin-25 
measurements in serum and urine 
Decrease in hepcidin concentrations in serum samples due to multiple freeze-thaw 
cycles is of minor importance compared to those in urine (Figure 6). Preliminary 
results from urine samples stored at -80°C and -20°C during a 6-month course 
showed that (a) hepcidin was stable only at -80°C and (b) addition of protease 
inhibitor phenylmethylsulfonyl fluoride19 had no beneficial effect (unpublished 
observations).  
Hepcidin concentrations in serum follow a clear circadian rhythm, such that the 
concentrations were 2- to 6-fold higher at 1500 than at 0600. Urinary concentrations, 
however, show a more blunted response, and thus less diurnal variation. The course 
of serum iron shows an inverse association with serum and urine hepcidin values 
(Figure 7).  
 
 
 
Figure 6. Influence of multiple freeze/thaw cycles on hepcidin reproducibility. 
Serum hepcidin (A), and urine levels (B) of different subjects measured after a freeze/thaw cycle for 
four times. Both serum and urine are expressed in Mega Intensity per liter in order to compare the 
influence of variation directly on measured MS signal. For serum analytical variation is probably a 
more important factor than the effect of multiple freeze/thaw cycles. 
 
Discussion 
The IMAC30 array-based urinary hepcidin assay correlates significantly with the 
previously described urinary hepcidin MS application using NP20 arrays8 and showed 
greater sensitivity and reproducibility, resulting in improved analytical performance. 
The increase in protein-binding capacity of the IMAC30 array makes it particularly 
suitable for serum analysis and measurement of low hepcidin concentrations in urine.  
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Figure 7. Circadian influence on urinary and serum hepcidin-25 concentrations. 
Urinary and serum hepcidin concentrations, and serum iron concentration in 3 healthy volunteers 
during a 24 hour time-course (Person A and C are pre-menopausal females, person B is male). 
Circadian influence is seen on all three parameters. Individual differences are visible on amplitude and 
frequency pattern, and relative concentration difference between urinary and serum hepcidin. Note 
that in subject A CRP-concentrations increased to 10 mg/L in the last 6 hr of the time-course, which 
suggests that an inflammatory process may have contributed to the persistent increase in hepcidin and 
the decrease in serum iron during this period. 
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The total assay variation includes analytical variation, biological or diurnal variation, 
and preanalytical variation, all contributing to the widening of ranges of the clinical 
utility clusters. In the future, we plan to routinely perform duplicate measurements and 
investigate isotope dilution20 or hepcidin derivatives as internal standards to reduce 
analytical variability. 
Biological variation in hepcidin concentrations due to a circadian rhythm correlated 
inversely with daily variations in serum iron concentrations21, in accordance with 
previous reports that transferrin receptors 1 and 2 on the outer hepatocyte membrane 
act as sensors of circulating iron and TS, thereby linking low serum iron with increased 
hepcidin synthesis22,23. Circadian rhythm may also lead to important variation in 
outcome if sampling time is not standardized, thereby contributing to the wide variation 
in hepcidin concentrations of the control population (Fig 5C). Sampling according to 
protocol led to decreased variation in hepcidin concentrations within the 
lipopolysaccharide group. The low variation within the iron deficiency anemia group is 
likely to be due to the dominant down-regulating influence of an iron-deficient 
erythropoiesis on hepcidin that prevents circadian increases. 
Variation in hepcidin results is also attributable to preanalytical conditions. According 
to our preliminary results, urine samples are more susceptible than serum to variation 
from multiple freeze-thaw cycles, which should be avoided, and urine samples should 
be stored at -80°C as soon as possible24,25.    
Measurement of serum and urine hepcidin by the same technique, and under the 
same circumstances, enabled comparison of serum with urinary values. Although their 
association was strong, confirming the previously reported correlation between 
hepcidin mRNA expression in liver cells and urinary hepcidin excretion26,  differences 
in serum en urine composition prohibit absolute comparison of analytical 
characteristics such as binding competition on the array surface and flight behavior 
during SELDI-TOF MS analysis27. Aspects such as ionization efficiency or ion 
suppression also can play a role and should be investigated in future studies. 
Meanwhile, difference in specimen behavior precludes calculations on the kinetics of 
hepcidin release by hepatocytes and its excretion from the blood into the urine. 
Construction of a calibration curve by addition of the same amount hepcidin-25 to 
dilution-serum or -urine confirms this effect, leading to speculation that a binding 
protein in serum prevents the binding of free hepcidin on the chip surface at low 
concentrations27. To circumvent differences in binding characteristics or possible 
matrix interferences, methodological approaches such as plasma fractionation27 or the 
use of magnetic reverse-phase beads28 have to be investigated for utility on hepcidin 
measurements. 
Our reported SELDI-TOF MS method detected all 3 isoforms of hepcidin, improved 
urinary hepcidin analysis, and enabled measurement of serum hepcidin by use of 
IMAC30 array. We show for the first time a high correlation of concentrations 
measured in corresponding serum and urine samples. Selection of the optimal body 
fluid for analysis, however, is influenced by preanalytical, analytical, and biological 
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variations that effect serum and urine differently. Urine is more vulnerable to multiple 
freeze-thaw cycles and storage temperatures other than -80°C, but less influenced by 
diurnal variation. Serum is more susceptible to circadian variation, and therefore 
standardization of sampling time is needed in clinical studies with serum. Serum is 
likely to be more sensitive than urine, however, for monitoring short-term kinetics of 
body hepcidin concentrations. Therefore, the specimen of first choice depends on 
study design and the practical aspects such as availability of materials and equipment.  
The ability to measure hepcidin in both serum and urine confirms that the learning 
process on hepcidin characteristics, kinetics, and clinical utility has only just begun. 
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Regulation of Hepcidin in Humans 
Abstract 
Knowledge of hepcidin regulation is foremost gained by in vitro studies. We 
aimed to translate this knowledge into the human in vivo situation. 
We measured serum markers as transferrin saturation (TS), soluble transferrin 
receptor (sTfR), and C-reactive protein (CRP) in parallel with hepcidin and 
prohepcidin in patients with iron metabolism disorders and controls. To 
assess sTfR as erythropoietic activity-associated factor in hepcidin regulation, 
we studied its influence on hepcidin expression in HepG2 cells. 
sTfR highly associated with erythropoietic activity that strongly interfered with 
the iron store regulation of hepcidin. HepG2 expression results display an 
inverse association between hepcidin and sTfR. Inflammation was strongly 
related to increased hepcidin levels regardless of the iron store and 
erythropoietic activity status. In contrast, prohepcidin failed to correlate to any 
other parameter.  
These studies verify that previous conclusions based on in vitro studies on 
hepcidin regulation are also likely to apply to human patients. This is 
underscored by a simple algorithm, based on parameters reflecting the main 
regulating pathways, that accurately predict the actual measured hepcidin 
levels. Future studies are needed to validate the combined utility of this 
predictive algorithm together with actual measured hepcidin levels in clinical 
diagnosis.  
 
Introduction 
The maintenance of body iron homeostasis requires mechanisms for the control of 
iron uptake and mobilization from stores, in order to meet erythropoietic needs, and 
for scavenging previously used iron. Therefore, the communication between cells 
that consume iron and cells that acquire and store iron must be tightly regulated1. 
Recent studies indicate that it is the liver produced peptide hormone hepcidin that 
plays this important role in the regulation of systemic iron homeostasis2,3 by directing 
the intestinal absorption and macrophage release of iron via the sole iron exporter 
ferroportin4,5.  
Recent work has identified three putative upstream pathways (i.e., iron store related, 
erythropoietic activity, and inflammation related) as well as a mandatory signaling 
pathway, which are in a way presumed to be interconnected. These pathways are all 
found to interact with liver cells to control the production of sufficient hepcidin for a 
proper maintenance of iron homeostasis6-11. Figure 1A (page 127) depicts a 
simplified model of hepcidin regulation that builds upon these recently acquired 
insights.  
Most of the evidence for this upstream regulatory model is obtained by molecular in 
vitro work and mice models applying recombinant techniques. Due to the 
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experimental set-up, such knowledge can not be directly transferred to the complex 
situation of aberrant iron homeostasis in human patients. In the present study, we 
aim to delineate these regulatory processes of hepcidin in humans with well-defined 
distortions of iron metabolism. This was done by the measurement of the serum iron 
indices, sTfR, and CRP, in healthy controls and in patients with documented iron 
deficiency anemia, acute inflammation, and thalassemia major. In separate in vitro 
experiments, we assessed the role of sTfR as an erythropoietic activity-associated 
factor in relation to hepcidin expression in the human hepatocytes cell line HepG2. 
As outcome parameters of the aforementioned regulatory processes we assessed 
serum hepcidin and prohepcidin by our recently developed mass spectrometry (MS) 
assay for serum12, and a commercially available prohepcidin enzyme-linked 
immunosorbent assay (ELISA) kit, respectively. Additionally, as a proof of principal, 
we developed an algorithm based on measured TS, sTfR and CRP levels by which 
hepcidin production can be estimated (Figure 1B, page 127) as a possible tool in 
clinical diagnosis along with actual measured hepcidin levels.  
 
Materials and Methods 
Study participants 
Iron Deficiency Anemia patients (n = 6; Hemoglobin male ≤ 8.3 mmol/L, female ≤ 7.3 
mmol/L; MCV ≤ 80 fl; ferritin ≤ 10 µg/L), were recruited during outpatient clinic visits 
at the Radboud University Nijmegen Medical Centre. Thalassemia Major patients (n 
= 5) treated with iron chelation therapy and multiple blood transfusions were 
recruited in Ospedale Sant ‘Eugenio, Rome, Italy. Samples obtained during the 
systemic inflammation response following experimental endotoxemia (n = 16) were 
collected from a human endotoxemia project13 after a single LPS injection on each of  
five consecutive days in healthy volunteers to mimic sub-chronic inflammation. 
Samples used were collected at day 5;  6 hours after LPS injection. Healthy 
volunteers were taken as controls (n = 20). Approval was obtained from the 
Radboud University Nijmegen Medical Centre institutional review board and written 
informed consent was obtained according to the Declaration of Helsinki. Samples 
were collected randomly between December 2005 and June 2006, all throughout the 
day, with exception of the endotoxemia samples that were sampled according to a 
tight time schedule. Thalassemia samples were collected at least 24 hours after the 
last chelation therapy administration.  
 
Laboratory measurements 
Total serum iron, latent iron binding capacity, and CRP levels were measured by 
Aeroset (Abbott Laboratories, Abbott Park, IL); serum ferritin was measured by 
Immulite 2000 and 2500 (Diagnostic Products Corporation, Los Angeles, CA). 
Routine hematology parameters were determined using flow-cytometry (Sysmex XE-
2100, Goffin Meyvis, Etten-Leur, The Netherlands). 
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sTfR was immunonephelometrically quantified with the use of polystyrene particles 
coated with monoclonal antibody specific to human sTfR on a BN II System (Dade 
Behring Marburg GmbH, Marburg, Germany). 
Serum non-transferrin bound iron (NTBI) levels were analyzed by a method based on 
iron mobilization and detection with iron chelators14. The assay uses oxalate as 
mobilizing agent, Gallium (III) as blocker of vacant transferrin sites, and Fl-aTf to 
provide the fluorescence signal detectable with a fluorescence plate reader15.  
Serum pro-hepcidin concentration was measured by an enzyme-linked immunoassay 
(Lot 12K096-2; DRG Diagnostics, Marburg, Germany). 
Serum hepcidin-25 measurements by surface-enhanced laser desorption/ionization 
time-of-flight (SELDI-TOF) MS were performed as previously reported12 with the use 
of IMAC30 ProteinChip arrays (Ciphergen Biosystems, Fremont, CA). Mass-to-
charge (m/z) spectra were generated using a Ciphergen Protein Biology System IIc 
TOF mass spectrometer. Peak annotation was performed with Ciphergen 
ProteinChip Software (version 3.2.0). Concentrations of serum hepcidin-25 were 
expressed as mega intensity units per liter. 
 
Hepcidin prediction by measured TS, sTfR, and CRP levels 
Based on the known main regulators (Figure 1, page 127) we created an algorithm to 
predict relative hepcidin levels in relation to the levels found in controls. By using sTfR 
(mg/L) and TS (%) as biochemical erythropoietic activity and the iron store, 
respectively, and CRP (mg/L) as indicator of inflammation, the following algorithm was 
defined:                
                                                            Equation 1 
(TS-sTfR )+CRP=Hepcidin
 
It contains the interconnection of the iron store and the erythropoietic activity with the 
latter as suppressor of hepcidin induction, and inflammation as a more independent 
regulator on top of the other two. 
The outcome of the algorithm is expressed as a relative value. Therefore the 
measured values of each parameter are transformed by use of equations 2,3 and 4  
before importation in the algorithm (equation 1): 
 
             Equation 2        Equation 3                     Equation 4 
Control
Control
i ME
ME
(TS - TS )
TS=
TS
Control
Control
i ME
ME
(sTfR - sTfR )
sTfR=
sTfR
Control
Control
i ME
ME
(CRP- CRP )
CRP=
CRP
 
                                i: individual value; MEControl : median value of the control group  
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The algorithm does not correct for the differences in the relative contribution of the 
respective parameters to the hepcidin levels and therefore only provides a rough 
estimation. 
 
HepG2 Cell culture 
The human hepatocyte cell line, HepG2 (American Type Culture Collection, 
Manassas, VA) was cultured in a humidified 37°C incubator with 5% CO2 using PC-1 
serum-free medium (Cambrex, Walkersville, MD). Because HepG2 are slowly dividing 
cells, to mimic in vivo conditions optimally, confluent hepatocytes were treated with 
10% serum of 15 different subjects (5 controls, 5 patients with iron deficiency, and 5 
patients with thalassemia major, respectively), for 78 hours, prior to the analysis of 
hepcidin expression levels.  
 
RNA isolation and real-time quantitative polymerase chain reaction 
Isolation of total RNA from the serum-treated HepG2 cells and subsequent cDNA 
synthesis were performed as described previously16. Real-time polymerase chain 
reactions (PCR) of human hepcidin transcripts and, for normalization of expression, 
the housekeeping gene hypoxanthine phosphoribosyltransferase (HPRT)16, were 
performed in a 25 µl total reaction using TaqMan Universal Master Mix (PE Applied 
Biosystems, Foster City, CA). After enzyme activation for 10 minutes at 95°C, 40 two-
step cycles were performed (30 seconds, 95°C; 1 minute, 60°C) in an ABI Prism 7700 
(PE Applied Biosystems). All primers and probes were purchased from PE Applied 
Biosystems (Hepcidin, assay no. Hs00221783_m1; HPRT, assay no. 4310890E). 
 
Statistical analysis 
Analyses were performed with GraphPad Prism software (version 4.0) (GraphPad 
Software, Inc, San Diego, CA). Group differences were calculated by non-parametric 
1-way analysis of variance (ANOVA) with Dunn´s post-hoc test.  Group comparison 
was estimated by Pearson correlation test. P values < 0.05 were considered 
significant.  
 
Results  
sTfR, TS, CRP, hepcidin and prohepcidin  levels in disorders of iron metabolism 
sTfR, TS and CRP are markers of erythropoietic activity, iron store and inflammation, 
respectively, representing putative upstream pathways of hepcidin regulation. These 
variables were measured in the serum of controls, patients with iron deficiency 
anemia, thalassemia major, and volunteers exposed to 2 ng/kg E. coli endotoxin to 
induce acute systemic inflammation.  
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Figure 2. Laboratory results of biochemical parameters representing regulatory pathways of 
hepcidin. Box plots show 25 and 75 percentile with median, and error bars represent minimum and 
maximum values. * indicates significant difference from control group (p < 0.05; non-parametric 1-way 
ANOVA with Dunn’s post-hoc test). LPS: healthy volunteers injected with LPS; IDA: iron deficiency 
patients; TM: Thalassemia Major patients treated with blood transfusions and iron chelators.  
 
We found that sTfR concentrations were strongly increased in both iron deficient and 
thalassemia major patients (Figure 2A), while the endotoxin-treated group displayed 
no difference compared to controls. TS was found to be around 100% in thalassemia 
major and less than 10% in iron deficiency anemia, while the endotoxemia group 
showed average levels that did not differ from  control values (Figure 2B). As shown in 
Figure 2C, for NTBI levels similar differences between the groups were observed as 
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for TS levels. Correlation analysis illustrates a strong  association between TS and 
NTBI (R = 0.958; P<.001, data not shown).  
CRP levels were only elevated in the endotoxin-treated group (Figure 2D), which 
showed the highest serum hepcidin values (Figure 2E) with a non-significant 
decrease in serum iron levels (data not shown). Hepcidin levels are highest during 
inflammation, patients with iron deficiency and thalassemia major show decreased 
hepcidin levels (Figure 2E). In contrast to hepcidin, serum prohepcidin levels 
displayed no significant difference between all the groups tested (Figure 2F), 
although the iron deficiency anemia patients showed a tendency to the overall lowest 
values, and the endotoxin-treated group the overall highest values. Furthermore, 
prohepcidin level did not correlate to serum hepcidin level or any other parameter 
tested in this study (results not shown).  
  
 
Figure 3. Serum Hepcidin-25 levels in relation to transferrin saturation levels in various iron 
metabolism disorders. Bracket lines give a rough indication of clusters of disorders of iron 
metabolism of similar etiology. Compared to the control population, TM patients show a small inter-
individual variation of low hepcidin levels, even in the presence of fully saturated transferrin levels. IDA 
patients consistently show very low serum hepcidin levels that seem to be apparent for TS levels of 
15% and below. The LPS group shows TS values within the reference range, but their hepcidin levels 
highly exceed those of the controls which suggests that inflammation acts as an additional regulating 
factor on top of the store regulation.   
 
 Serum hepcidin in relation to TS 
To visualize possible interplay of the erythropoietic and inflammatory regulators with 
the store regulator, serum hepcidin concentrations were displayed in relation to TS 
values for every specific group measured (Figure 3). In the presence of physiological 
iron stores in the control group, serum hepcidin levels range from 0.58 to 9.95 M 
Intensity/L, whereas in case of deficient iron stores (IDA), hepcidin levels were 
consistently low. However, the relationship between TS and hepcidin became less 
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apparent for patients with thalassemia major and volunteers injected with endotoxin. 
Specifically in thalassemia major, the serum hepcidin levels appeared to be too low 
for the highly elevated TS levels. Furthermore, in these patients inter-individual 
differences in hepcidin levels are reduced in comparison to the control group. The 
endotoxin group displayed slightly lower serum iron levels with a similar variation in 
TS as the reference group but higher levels of serum hepcidin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Control 
(n=5) 
IDA 
(n=5) 
TM 
(n=5) 
TS (%) 28 (14 - 44) 8 (5 – 10) 98 (85 – 110) 
Ferritin (µg/L) 48 (22 - 109) 6 (6 – 10) 784 (272 - 1710) 
CRP (mg/L) < 5 < 5 < 5 (< 5 - 6) 
sTfR (mg/L) 0.92 (0.82 – 1.28) 2.64 (2.16 – 4.24) 6.03 (2.15 – 6.47)
NTBI (µmol/L) 1.78 (1.24 – 2.14) 0.46 (0.12 – 0.79) 3.99 (3.39 – 4.91)
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Hepcidin mRNA 
expression in HepG2 cells in 
relation to sTfR concentrations of 
human sera. 
Panel A: Relative hepcidin 
expression measured in HepG2 cells 
after 72 hr incubation with 10% 
serum of 5 healthy controls, 5 iron-
deficient patients (IDA), and 5 
thalassemia major patients (TM). 
Laboratory characteristics of the 
used sera are displayed as median 
(range). Expression levels in IDA- 
and TM-treated cells is significant 
lower than in the control cells (* 
indicates p < 0.05). Panel B shows a 
strong association between the 
expressed hepcidin levels and the 
sTfR levels in the sera added.  
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sTfR as erythropoietic activity derived regulation factor 
To assess the relation of sTfR as erythropoietic activity-associated factor with 
hepcidin production, we studied the influence of serum addition on hepcidin 
expression in the human hepatocytes cell line HepG2. Compared to controls, sera 
from IDA and TM patients containing elevated sTfR levels, significantly decreased 
hepcidin expression (Figure 4 A). The relative hepcidin expression values strongly 
correlated to the measured sTfR values (R = 0.923; P < .0001; Figure 4B). 
 
Figure 5. Hepcidin prediction by an algorithm based on measured TS, sTfR, and CRP levels. 
epcidin estimation by measured TS, sTfR, and CRP levels 
nd inflammation are the 
Levels display the relative difference to the control group. Box plots show 25 and 75 percentile with 
median, and error bars represent minimum and maximum values. Dotted line indicates relative level of 
control population. LPS: healthy volunteers injected with LPS; IDA: iron deficiency patients; TM: 
thalassemia major patients treated with blood transfusions and iron chelators. A) Predicted hepcidin 
levels calculated by an algorithm containing all regulators (TS – sTfR) + CRP. B) Predicted hepcidin 
levels calculated by reduced algorithm (TS – sTfR) simulating the effect of inflammation (CRP). C) 
Predicted hepcidin levels calculated by reduced algorithm (TS) + CRP simulating the effect of 
erythropoiesis (sTfR). D) Predicted hepcidin levels calculated by reduced algorithm (– sTfR) + CRP 
simulating the effect of the iron store (TS). 
 
H
As our data suggest that erythropoietic activity, iron store a
major determinants for hepcidin expression in humans, we evaluated whether a simple 
algorithm based on measured TS, sTfR, and CRP levels could predict the measured 
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hepcidin levels. Figure 5A shows that the predicted hepcidin levels closely resemble 
the actual measured levels in the studied groups as depicted in Figure 2E. Linear 
regression analysis resulted in a strong significant correlation between the calculated 
and measured serum hepcidin levels (R = 0.756, P < .001; results not shown). By 
alternating omission of one of the parameters from the equation, we were able to 
assess the effect of each regulator on the out come level of hepcidin under different 
conditions (Figure 5B-D). When CRP was left out of the equation, this only influenced 
the hepcidin levels in the endotoxin-treated group (Figure 5B), whereas omission of 
sTfR considerably affected both the iron deficiency anemia and thalassemia major 
group. TS omission most of all changed the level of the thalassemia major group 
(Figure 5D).  
 
Discussion 
d animal studies indicate that iron stores, erythropoietic activity and 
m TS (iron store), sTfR (erythropoietic activity) 
In vitro work an
inflammation are involved in regulation of hepcidin production. Insights in the present 
study are based on a few small groups of patients with distinct iron disorders. Samples 
were randomly collected throughout the day and therefore might be influenced by 
diurnal rhythm. This is especially the case for parameters such as serum hepcidin 
thereby affecting its potential to differentiate between disorders of iron metabolism12. 
Nevertheless, we observed differences in serum hepcidin levels between various 
diseases indicating that the inter-patient variation exceeds this confounding aspect of 
the intra-individual circadian variation.  
We defined an algorithm based on seru
and CRP levels (inflammation) to predict hepcidin levels and evaluated the algorithm 
in patients with different iron metabolism disorders. Based on today’s knowledge that 
the Hemojuvelin (HJV)-related pathway is more mandatory than regulatory and the 
inaccessibility of a marker of this pathway such as soluble HJV17 resulted in an 
algorithm that only comprises the three main regulatory pathways. The choice to 
select TS instead of ferritin as reflecting parameter of iron store is based on its 
proposed direct interaction with TfR1 and TfR2 as part of the iron sensor complex, and 
the strong correlation between levels of hepcidin predicted by an algorithm containing 
TS values and that in which TS is replaced by log ferritin values (R = 0.978; P< .001; 
results not shown). Although the selected parameters all have their own shortcomings 
as measures of the putative regulatory pathways of hepcidin, together with the 
absence of weight ascribed to any of the regulators in this preliminary phase, the 
algorithm based on these widely available and routine used laboratory indices predicts 
the serum hepcidin values with a high accuracy. This suggests that although hepcidin 
is regulated by a complex network, these three regulatory “highways” set the level of 
hepcidin production and that under different conditions fine tuning might occur by 
many “side roads” and “interconnections”. Larger studies should validate the 
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robustness and suitability in clinical differentiation of this algorithm in combination with 
actually measured hepcidin levels. 
The effect of erythropoietic regulation of hepcidin is shown to be especially strong for 
iron deficient and thalassemia patients18,19. Hepcidin levels in these patients are 
substantially decreased in the presence of clearly elevated levels of serum sTfR20. 
The relative wide range in sTfR concentrations in the thalassemia patients (Figure 
2A) suggest individual differences in erythropoietic drive. Combined with differences 
in iron burden, this might explain the variation in serum hepcidin levels21 as displayed 
in Figure 2E. Our algorithm corroborated these findings. Also our in vitro results 
expand recent reports indicating sTfR as possible candidate for the erythropoiesis 
related regulator9,22. Although the results are no proof of a causal relation because of 
the presence of other serum components, they show a strong association between 
the down-regulated hepcidin expression in hepatocytes cell line and increased sTfR 
levels from patient serum added to the cell medium. The contradiction between these 
results and recently published absence of an effects of sTfR on iron absorption and 
hepcidin expression in mice23 and the presence of other potential candidates24 show 
that more research is needed in the quest for the communicator between the iron 
consuming bone marrow and hepcidin producing liver cells.  
Elevated iron stores, marked by increased iron saturation of transferrin is predicted to 
induce hepcidin production in order to decrease iron absorption and demonstrated as 
such in healthy volunteers treated with oral iron25. In the present study, the elevated 
TS values in thalassemia major patients were not associated with increased hepcidin 
levels. The anemia driven erythropoietic regulation clearly overruled the iron store 
regulation by decreasing hepcidin production8,22,26. Results from the algorithm indeed 
display a strong counter activity of iron store and erythropoietic regulation in these 
patients.  
Inflammation-induced hepcidin production appears to occur by a rather dominant 
pathway as is illustrated by the high hepcidin levels measured in the endotoxin-treated 
group in the presence of slightly decreased serum iron levels. To the best of our 
knowledge human in vivo studies on the interaction of the inflammatory hepcidin 
regulatory pathways with that of the mandatory HJV/SMAD, iron store and 
erythropoietic networks have not been done. In vitro investigations, however, on the 
role of the HJV/SMAD pathway in case of inflammation showed that human Hep3B 
cells pre-treated with HJV small interfering (si)RNA were capable of a 4-fold hepcidin 
induction in response to IL-6, equal to control cells27. Next to this, HJV-/- mice were 
able to induce hepcidin after LPS, IL-6, or TNFα injections, although the response was 
less compared to controls28. Overall, the results of several mice studies point in the 
direction that inflammation also acts independently from the iron store and erythroid 
pathways29-31. We observed that in two iron deficient human volunteers (values: serum 
iron 7-7 µmol/L; ferritin 7-8 µg/L; TS 10.5-10.8%), the extent of endotoxemia-mediated 
hepcidin induction from low baseline values was similar to the relative induction in 
subjects that were not iron deficient (unpublished data). Taken together, our human in 
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vivo data are in agreement with previous reported molecular in vitro work and mice 
studies and indicate that inflammation increases hepcidin production in such a way 
that it can be added on top of the level set by the other regulators.   
Our current as well as previously reported data15 show a strong  correlation between 
TS and NTBI which indicates that if NTBI regulation of hepcidin is involved, its 
influence is closely related to the iron store regulator. Further research must reveal the 
differential roles of NTBI and TS as upstream store regulators of hepcidin. 
 In conclusion, in the present study we show that with the use of biochemical serum 
analyses we were able to i)  give insight in the interrelation of inflammation, 
erythropoiesis, and iron store regulating processes of hepcidin; ii) verify that previous 
conclusions based on mouse models of aberrant iron homeostasis are likely to apply 
to human patients; iii) indicate sTfR as a potential candidate for regulation of hepcidin 
production, and iv) create an algorithm that is suitable to estimate the contribution of 
the main regulators to the serum hepcidin levels during various conditions in humans 
in vivo. Future studies have to demonstrate the clinical utility of this predictive 
algorithm along with the actually measured hepcidin levels in a clinical setting.  
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LPS-IL-6-Hepcidin axis in Human Endotoxemia Model 
Abstract 
Hepatic peptide hormone hepcidin is the key regulator of iron metabolism and 
the mediator of anemia of inflammation. Previous studies indicated that 
interleukin-6 (IL-6) mediates hepcidin increase and consequent hypoferremia 
during inflammation. Here we used an in vivo human endotoxemia model to 
analyze the effects of lipopolysaccharide (LPS) as a more upstream 
inflammation activator. The temporal associations between plasma cytokines, 
hepcidin levels, and serum iron parameters were studied in 10 healthy 
individuals after LPS injection. IL-6 was dramatically induced within 3 hours 
after injection and urinary hepcidin peaked within 6 hours, followed by a 
significant decrease in serum iron. Serum prohepcidin showed no significant 
change within a 22-hour time frame. 
These in vivo human results confirm the importance of the IL-6-hepcidin axis in 
development of hypoferremia in inflammation and highlight the rapid 
responsiveness of this iron regulatory system. 
 
Introduction 
Anemia of chronic disease occurs in patients with acute and chronic immune 
activation and represents an important clinical problem. It is a condition that has also 
been termed “anemia of inflammation” and that is thought to be mediated by 
hepcidin1, a small, cysteine-rich cationic peptide, produced by hepatocytes2-4. 
Furthermore, hepcidin is proposed to be the key regulator of iron metabolism. 
Hepcidin overexpression in patients with hepatic adenomas5 or in transgenic mice6 
resulted in severe iron-refractory microcytic anemia. Conversely, hepcidin deficiency 
in humans7 or mice8 has been associated with severe iron overload. Hepatic hepcidin 
expression is suppressed by hypoxia and anemia9, and induced by iron stores, and 
inflammation4.  
The induction of hypoferremia by inflammation is commonly seen in many infectious 
diseases. However, the mechanism remained unknown until the involvement of 
hepcidin was demonstrated in mice injected with bacterial lipopolysaccharide (LPS) 
or turpentine oil4,9. Importantly, hepcidin-deficient mice did not develop hypoferremia 
after turpentine injection9. In humans, increased urinary hepcidin levels were 
detected in patients with chronic infections or severe inflammatory diseases10. In 
human hepatocyte cultures, hepcidin expression was induced after direct exposure to 
LPS or medium from LPS-activated human monocytes, and this response could be 
ablated by the addition of anti-interleukine-6 (anti-IL-6) antibodies. Furthermore, IL-6 
infusion in human volunteers rapidly induced hepcidin and hypoferremia11, whereas 
IL-6 knock-out mice injected with turpentine failed to increase hepcidin and develop 
hypoferremia. 
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In the present study, we used an in vivo human endotoxemia model to study the 
temporal associations between different plasma cytokines, urinary hepcidin, and 
serum iron. We demonstrate the existence of a highly responsive LPS-IL-6-hepcidin 
axis linking innate immunity and iron metabolism. 
 
Study design 
Research subjects 
After approval from the local ethics committee was received, 10 healthy individuals (4 
man, 6 women; mean age 21; range 18-24 years) gave written informed consent to 
participate in this study. Individuals who were taking prescription drugs (except for 
oral contraceptives) or aspirin or other nonsteroid anti-inflammatory drugs were 
excluded. All research subjects were HIV- and hepatitis B-negative and had not had 
any febrile illness in the 2 weeks preceding the study. For 10 hours prior to the 
experiment, research subjects refrained from caffeine, alcohol and food. Approval for 
these studies was obtained from Radboud University Nijmegen Medical Centre’s 
institutional review board. 
 
Study protocol 
Research subjects were intravenously injected with a bolus of 2 ng/kg body weight 
Escherichia coli O:113 LPS (United States Pharmacopeial Convention, Rockville, 
MD) between 8 and 9 AM. Blood and urine samples were taken just before LPS 
injection  and serially thereafter at regular time intervals up to 22 hours. In the hour 
prior to the LPS administration research subjects were prehydrated with 1.5 L 
glucose (glc) 2.5% NaCl 0.45%. During the experiment, research subjects received 
150 mL/h glc 2.5% NaCl 0.45%. Serum iron parameters, ferritin, C-reactive protein 
(CRP), prohepcidin, urinary creatinine, plasma cytokines, and routine hematology 
parameters were determined at the Radboud University Nijmegen Medical Centre, 
The Netherlands. Urines were preserved with 0.05% sodium azide, and shipped 
frozen to UCLA, Los Angeles, CA., for urinary hepcidin measurement. 
 
Laboratory measurements 
Total serum iron and latent iron binding capacity (LIBC) were measured using 
ascorbate/FerroZine colorimetric method, and urine creatinine was measured by 
colorimetric detection with picric acid (Roche Diagnostics, Mannheim, Germany). 
CRP was measured using immunologic agglutination detection with latex-coupled 
polyclonal anti-CRP antibodies (Abbott Laboratories, Abbott Park, Illinois), all 
measured by Aeroset (Abbott Laboratories, Abbott Park, Illinois). The serum ferritin 
was measured by a solid-phase, 2-site chemiluminescent immunometric assay 
(Immulite 2000, Diagnostic Products Corporation, Los Angeles, CA). 
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Routine hematology parameters were determined using flow cytometry (Sysmex XE-
2100, Goffin Meyvis, Etten-Leur, The Netherlands). 
Tumor necrosis factor-α  (TNF-α), IL-6, IL-1β, IL-12, IL-10 and interferon-γ (IFN-γ) 
were measured in one batch, using a multiplex Luminex Assay12 (Luminex, Austin, 
TX). 
Serum prohepcidin concentration was measured by enzyme-linked immunoassay 
using a commercially available kit (DRG Diagnostics, Marburg, Germany). 
Urinary hepcidin assay was performed as previously described11. Cationic peptides 
were extracted from urine using CM-Macroprep (BioRad Laboratories Inc., Hercules, 
CA). Hepcidin concentrations were determined by an immunodot assay. Urine 
extracts equivalent to 0.1 to 0.5 mg of creatinine were dotted on Immobilon-P 
membrane (Millipore, Bedford, MA) along with a range of synthetic hepcidin 
standards (0 to 80 ng). Hepcidin was detected using rabbit anti-human hepcidin10 
antibody with goat anti-rabbit horseradish peroxidase (HRP) as a secondary 
antibody. Dot blots were developed by the chemiluminescent detection method 
(SuperSignal West Pico Chemiluminescent Substrate, Pierce Chemical, Rockford, IL) 
and quantified with the Chemidoc cooled camera running Quantity One software 
(Bio-Rad Laboratories). Hepcidin quantity in each sample was normalized using 
urinary creatinine, and urinary hepcidin levels were expressed as nanograms of 
hepcidin per millimole of creatinine. 
 
Statistical analysis 
Statistical analyses were performed with GraphPad Prism software (version 4.0). 
Differences were tested for statistical significance by 1-way repeated measurements 
analysis of variance (ANOVA) or 1-way ANOVA.  
 
Results and discussion 
Injection of 2 ng/kg LPS induced a hypoferremic effect (Figure 1A) already detectable 
6 hours after injection and reaching a 57% fall in serum iron after 22 hours. 
Importantly, the changes in urinary hepcidin preceded serum iron decrease (Figure 
1B). Maximal hepcidin excretion was detected at 6 hours after injection, after which 
the levels started declining but were still higher than preinjection levels at 12 to 22 
hours. This time course of hepcidin induction and serum iron decrease was similar to 
the one observed in volunteers infused with IL-611. Hepcidin was recently shown to 
regulate cellular iron efflux in vitro by binding to the iron efflux channel ferroportin and 
inducing its internalization and degradation13, and this mechanism could explain the 
rapid development of hypoferremia observed in research subjects who had been 
injected with LPS. 
Daily, macrophages export around 20 mg of iron through ferroportin, and the iron is 
taken up largely by the developing erythrocytes in the bone marrow. However, the 
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plasma transferrin compartment contains only 2 to 4 mg of iron, which therefore must 
turn over every few hours. Accordingly, blocking macrophage iron efflux would be 
expected to decrease plasma iron concentration within hours.  
 
 
Figure 1.  Laboratory measurements. Serum iron (A), urinary hepcidin (B), serum prohepcidin (C), 
and CRP (D) were measured in 10 healthy volunteers more than 22 hours after LPS injection. Each 
point represents the mean ± SEM. Significant differences are indicated ( *1-way repeated 
measurements ANOVA; **  1-way ANOVA). 
 
Hepcidin is also known as a type II acute-phase protein10 and, in chronic 
inflammatory conditions, increased hepcidin levels correlate with increased ferritin 
levels. We measured acute-phase reactants CRP and ferritin, in research subjects 
injected with LPS. CRP increased after LPS injection, but the time course lagged 
after hepcidin, with maximum levels detected 22 hours after injection (Figure 1D). 
Serum ferritin levels increased only slightly after 6 hours (results not shown) and 
stayed within normal reference intervals (10 to 150 µg/L) up to 22 hours, indicating 
that ferritin acute-phase response is probably delayed in comparison to hepcidin. The 
rapidity of the hepcidin response could be related to its proposed role as an inducer 
of hypoferremia that would restrict the flow of essential iron to infecting microbes, and 
slow their multiplication in tissues. This host response could be particularly valuable 
during the earliest phases of infection, before other components of the innate and 
adaptive immunity are fully mobilized14. 
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Figure 2.  Plasma cytokine levels. Plasma levels of TNF-α (A), IFN-γ (B), IL-6 (C), and IL-10 (D) 
were measured in 10 healthy volunteers more than 4 hours after LPS injection. Each point represents 
the mean ± SEM. Peak values are indicated (▼).  
 
LPS injection in human volunteers induced a cytokine response characteristic of  
inflammation15. After an early and transient induction of the proinflammatory 
cytokines TNF-α, and INF-γ, the acute-phase response was boosted by a dramatic 
increase in IL-6, which peaked at 3 to 4 hours after LPS injection (Figures 2 A-C). IL-
1β expression, on the other hand, showed no significant changes within 4 hours, and 
IL-12  was undetectable in all research subjects (results not shown). Literature shows 
that anti-inflammatory cytokines, like IL-10, are able to counteract the 
proinflammatory IL-1β and IL-12 production15. In this study we observed a transient 
increase in IL-10 that peaked at 2 to 3 hours after injection (Figure 2D), which might 
explain the mentioned cytokine suppression. The time course of IL-6 increase in 
relationship to hepcidin induction and serum iron decrease coincides with that 
observed in research subjects injected directly with IL-611. 
Serum prohepcidin levels showed no significant change within the 22-hour period 
(Figure 1C). Previous reports on serum prohepcidin measurements also showed lack 
of correlation with other iron parameters and only minor concentration differences 
between various patient populations with disturbed iron metabolism16. It remains to 
be determined if the lack of correlation between the urinary hepcidin and serum 
prohepcidin measurements is due to technical limitations of serum assays or if serum 
prohepcidin concentration does not reflect inflammation or iron metabolism changes. 
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In conclusion, our in vivo human endotoxemia model highlights the role of hepcidin at 
the interface between host defense and iron regulation, and further supports the 
importance of 
IL-6-hepcidin axis in the development of hypoferremia and anemia of inflammation. 
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Nitric Oxide Contribution to Inflammatory Hypoferremia 
 
Abstract 
Recent studies indicate an important role of hepcidin in the redistribution of 
iron between the intra- en extra-cellular body compartments during 
inflammation. In vitro studies suggest that nitric oxide (NO) is also involved in 
cellular iron shifts.  
In order to value the effect of NO on iron metabolism in vivo, we examined 
human volunteers injected with lipopolysaccharide in the absence (LPS group, 
n = 6) and presence (LPS + AG group, n =6) of selective inducible NO synthase 
(iNOS) inhibitor aminoguanidine. We compared the course of iron parameters, 
cytokine profiles and urine hepcidin levels between both groups. 
These studies showed that C-reactive protein, Tumor necrosis factor-α, and 
Interleukin (IL)-10, urinary hepcidin excretion levels and circulating iron levels 
showed no significant differences between the LPS and LPS + AG groups. 
These data indicate that, compared to hepcidin, NO plays no role of 
significance in iron homeostasis during systemic inflammation. 
  
Introduction 
A highly prevalent clinical problem that occurs in patients with acute and chronic 
immune activation is the development of a condition termed ‘anemia of inflammation’. 
As an important host defense strategy, mammals use the high vulnerability of 
infecting microbes for iron starvation by iron sequestration into iron-binding proteins 
and locations less accessible1. A currently accepted model in which hepcidin takes a 
central place as inducer of hypoferremia during inflammation2 indicates that cytokines 
like IL-6 and IL-1β play a role as upstream activators of hepcidin production3-6. 
Hepcidin blocks the iron exporter ferroportin in macrophages and enterocytes7, 
leading to hypoferremia, and eventually causes anemia as a negative clinical side 
effect. 
Besides hepcidin, Nitric Oxide (NO) as a product of inducible NO synthase (iNOS), 
also plays an important role in various pathophysiological mechanisms during 
systemic inflammation and sepsis8. Until now, only in vitro experiments have shown 
that intracellular activation of the iron responsive element 1 (IRP1) by NO is 
demonstrated to promote an increase in cellular uptake from transferrin-bound serum 
iron9,10. To our knowledge, interactions between NO and hepcidin have not been 
reported. 
Mediators such as lipopolysaccharide (LPS) and the proinflammatory cytokines IL-1β, 
IL-2, IL-6, Tumor necrosis factor-α (TNF-α), and Interferon-γ are able to induce 
iNOS11, which is expressed in a variety of cells, including vascular endothelial cells, 
smooth muscle cells, different parenchymal cells and macrophages12. However, the 
role of NO in shifting iron from the extra- to the intracellular compartment during 
acute inflammation and therefore its contribution to the development of hypoferremia 
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under these conditions is controversial because of the discrepancy in results of 
different in vitro studies13-16. 
In order to value the contribution of NO to iron regulation in vivo during inflammation, 
we utilized an experimental endotoxemia model in human volunteers in whom LPS 
was injected followed by an infusion of the selective iNOS inhibitor aminoguanidine 
(AG)17, of which we have previously demonstrated that it significantly inhibits NO 
production during endotoxemia18. Besides serum iron, inflammation parameters, 
together with plasma cytokine levels and urine hepcidin levels, were compared with 
results obtained during human endotoxemia without iNOS inhibition5. 
 
 
Study design 
Subjects 
After approval from the Radboud University Nijmegen Medical Centre institutional 
review board and the local ethics committee, healthy, nonsmoking subjects gave 
written informed consent according to the declaration of Helsinki to participate in this 
study. Those who were taking prescription drugs, aspirin or other nonsteroid anti-
inflammatory drugs were excluded (except for oral contraceptives).  
All subjects were HIV and Hepatitis B negative. They did not have a febrile illness in 
the 2 weeks preceding the study. Ten hours prior to the experiment, all subjects 
refrained from caffeine, alcohol and food and showed no significant difference in 
dietary intake of nitrate in the days before the experiment (data not shown). The 
subjects who received LPS in the absence of AG were previously described5. 
 
Study protocol 
In the hour prior to the LPS administration, all subjects were prehydrated with 1.5 
liters glucose 2.5% NaCl 0.45%, and during the experiment subjects received 150 
mL/h glucose 2.5% NaCl 0.45%.  
Between 8.00 and 9.00 AM, all test subjects were intravenously injected with a bolus 
of 2 ng/kg body weight LPS (Escherichia coli O:113; United States Pharmacopeia 
Convention, Rockville, Md., USA). In addition, the subjects in the LPS + AG group 
received an intravenous loading dose of 5 mM AG (Clinalfa, Switzerland) 1 hour after 
the administration of LPS, followed by a maintenance dose of 1.5 mM/h during 4 
hours. We previously reported that with use of this protocol, a significant reduction in 
urinary NO metabolite production, with an additional reduction in iNOS mRNA 
expression in cells isolated from urine was achieved18. To monitor the onset and 
alterations of endotoxin-induced symptoms, subjects were asked to score the 
severity of nausea, headache, shivering, muscle pain and back pain every 30 
minutes. Symptoms were scored on a scale ranging from 0 (symptom not present) to 
5 (worst ever experienced). Scores were added up to form a “total symptom score”. 
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During the experiment, all subjects were hospitalized for 24 hours at the Intensive 
Care Research Unit. Blood samples were taken just before LPS injection and serially 
thereafter at regular time intervals up to 22 hours. Urine samples were collected 
between 0-3 hr, 3-6 hr and 6-22 hr after LPS injection. Samples were centrifuged 
immediately after collection, divided into aliquots to avoid multiple freeze-thaw cycles 
and stored at –80°C. Hepcidin measurements were performed within 2 months after 
collection.  
 
Laboratory measurements 
Routine chemistry parameters -- total serum iron, latent iron-binding capacity, urine 
creatinine and C-reactive protein (CRP) -- were measured by Aeroset (Abbott 
Laboratories). Cytokine levels were analyzed batch-wise using a multiplex Luminex 
Assay  (Luminex, Austin, Tex., USA). 
Urinary hepcidin measurements by surface-enhanced laser desorption/ionization 
time-of-flight mass spectrometry (SELDI-TOF MS) on NP20 ProteinChip array 
(Ciphergen Biosystems, Fremont, Calif., USA) were performed as previously 
reported19. Peak annotation was established with Ciphergen ProteinChip Software 
(version 3.2.0).  
 
Statistic analyses 
Values are presented as means with standard error of the mean (SEM). Statistical 
analyses were performed with GraphPad Prism 4.0 software (GraphPad Software 
Inc., San Diego, Calif., USA). Differences between groups were tested for statistical 
significance by 2-way analysis of variance (ANOVA) with repeated measurements 
using SPSS 12.0.1 (SPSS Inc., Chicago, Ill., USA). P < 0.05 was considered 
significant. Because of the between-batch variability for all cytokine measurements 
and the analytical variability of the urinary hepcidin assay, for statistical analysis, 
relative values were used (expressed as percentage increase/decrease in relation to 
baseline values) but displayed as absolute values in Table 1. 
 
 
Results and discussion 
The role of NO in the development of hypoferremia remains controversial as, until 
now, only some in vitro experiments have suggested that activation of IRP1 by 
certain redox species of NO promote an increase in cellular uptake from transferrin-
bound serum iron10. In order to evaluate the effect of NO on the iron metabolism in 
vivo, we compared iron parameters, cytokine profiles and urine hepcidin levels in 
human volunteers injected with LPS in the absence and presence of the selective 
iNOS inhibitor AG. Demographic characteristics are shown in Table 1. 
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Table 1. Demographic and laboratory characteristics of study groups. 
LPS (n = 6) 
 
LPS+AG(n = 6) 
 
 
Baseline Peak value Baseline Peak value 
LPS versus 
LPS + AGb 
(p value) 
    
 Sex, male:female     1:5       3:3   
 Age, years    
         Mean     20        22   
         Range     18 - 24  20 - 25   
Vital Characteristics      
         Body temperature, °C  36.6 ± 0.2     38.1 ± 0.3*    36.2 ± 0.1     37.7 ± 0.2* 0.879 (ns) 
         Total symptom score       0 4.3 ± 0.6*         0 5.3 ± 2.1* 0.855 (ns) 
Inflammatory parameters      
         TNFα, pg/mLa   ≤ 8     860 ± 244*      ≤ 8      349 ± 91* 0.099 (ns) 
         IL-6, pg/mLa    12 ± 4.0 6,449 ±  1,944*      ≤ 8 1,283 ± 358*, +    0.033 
         IL-10, pg/mLa   ≤ 8       89 ± 17.6*      ≤ 8      142 ± 50* 0.609 (ns) 
         CRP, mg/L      8 ± 3.5       43 ± 6.8*      ≤ 5        33 ± 3.6* 0.545 (ns) 
          WBC, × 109 /L   6.3 ± 0.5    14.5 ± 1.6* 4.8 ± 0.3     12.8 ± 1.1* 0.655 (ns) 
Iron related parameters      
          Urinary Hepcidin-25,  
          M Int/mmol creatininea
0.20 ± 0.09    6.16 ± 2.18* 0.84 ± 0.20  19.67 ± 5.65* 0.903 (ns)c
          Serum iron, µmol/L    21 ± 3.4         6 ± 0.6d,* 17 ± 2.9 10 ± 1.8d 0.222 (ns) 
      
 
Data are presented as means ± SEM (absolute values). WBC: white blood cell count; ns: not significant. 
aStatistic analysis for group differences, and differences between distinct time points was performed on relative values (in 
relation to baseline values). 
bDifference between LPS and LPS+AG group for the whole curve by 2-way ANOVA with repeated measures. 
cBased on relative cumulative hepcidin-25 excretion per mmol urinary creatinine values during 22 hr time-course. 
dNadir value instead of peak value. 
*P < 0.05 versus baseline value (paired sample t-test). 
+P < 0.05 versus LPS group (independent t-test). 
 
To our knowledge, direct influence of NO on cytokine induction is not reported and 
AG seems to be incapable of suppressing cytokine induction20. However, it should be 
noted that other pro- and anti-inflammatory cytokines like TNF-α and IL-10 (Table 1) 
and the acute phase protein CRP (Figure 1A) showed equal responses in both 
groups. In addition, increase in body temperature, total symptom score, and white 
blood cell count during the experiments were also comparable (Figure 1; Table 1). In 
contrast, the IL-6 response was weakly reduced in the LPS + AG group (Table 1), 
although the reason for this is unclear. Taken together, these results show that AG 
does not influence the inflammatory response during endotoxemia. 
Given the power of these experiments, no statistically significant levels were reached 
on serum iron and hepcidin excretion by the use of NO inhibitor AG (Figure 1B, C). 
These results suggest that the absence of a difference in hepcidin excretion between 
groups results in a similar reduction in iron levels. Taken together, inhibition of iNOS 
and subsequent diminished NO levels appear to have no effect on hepcidin 
production and do not lead to a difference in circulating iron levels.  
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Figure 1. Laboratory results at different time points after injection of LPS with or without AG as 
an iNOS inhibitor. Baseline and peak values of CRP (A) and serum iron (B) are shown together with 
relative cumulative hepcidin-25 excretion in urine (C). The values of humans injected with LPS are 
compared in the absence , and  presence  of AG. C: The values in the absence of AG are 
connected by a continuing line, whereas the values in the presence of AG are connected by a dotted 
line. For CRP and serum iron each point represents the mean ± SEM, whereas for hepcidin-25 
excretion, values are expressed as cumulative relative mean to baseline ± SEM. Data were analyzed 
by 2-way ANOVA with repeated measures over the complete curve and significant differences 
between both groups are indicated as P < 0.05.  
 
Interestingly, during acute inflammation, hypoferremia is likely to be foremost 
regulated by macrophages9. It is possible that the systemic inflammation induced by 
LPS infusion is too mild to induce iNOS in the macrophages. It was recently 
demonstrated that iNOS was not induced in peripheral blood mononuclear cells 
during human endotoxemia21. Also, in a previous study, Annane et al.22 did not detect 
iNOS in cells or vessels of the systemic circulation in patients with septic shock 
caused by cellulitis, but only at the site of infection suggesting a compartmentalized 
induction of iNOS. These studies, together with the data of our present report, 
suggest that NO does not contribute to hypoferremia during systemic inflammation in 
humans.   
In summary, our data show that iNOS-mediated NO production has no significant role 
in the induction of hypoferremia during acute and systemic inflammation in vivo in 
humans. This study confirms the profound role of hepcidin in inducing hypoferremia 
during acute inflammation.   
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Abstract 
After hemochromatosis was mapped to chromosome 6 by linkage to HLA in 
1976, two Dutch families with non-HLA-linked forms of hemochromatosis were 
reported. Indeed, since the identification of the HFE gene at least four other 
genes were found to be involved in hemochromatosis. We now report on one of 
these families with hemochromatosis 'unlinked' to HLA.  
Twenty family members were investigated for serum iron indices and urine 
hepcidin levels and for mutations in the HFE and hemojuvelin (HJV) genes. A 
new homozygous truncating mutation of the HJV gene was found to be 
responsible for one case of severe juvenile hemochromatosis. In this family, 
the characteristic C282Y variant in HFE was also common. The presence of the 
HJV mutation on one allele does not lead to elevated serum iron indices and 
decreased urinary hepcidin levels in heterozygous or homozygous HFE-related 
hemochromatosis. Therefore, it does not appear to be a modifier of HFE linked 
hemochromatosis. This finding is in accordance with recent findings on the 
position of HJV in the iron network, which is distinct from that of HFE. 
 
Introduction 
Iron overloading in hereditary hemochromatosis (HH), if left untreated, may lead to 
serious complications, such as skin pigmentation, arthropathy, diabetes mellitus, 
hypogonadism and other endocrinopathies, liver cirrhosis, liver cancer, and 
cardiomyopathy 1,2. Treatment usually consists of frequent phlebotomies. In the 
1970s HH was recognized as an autosomal recessive disorder linked to the short 
arm of chromosome 6 close to HLA-A 3. Feder and co-workers identified the 
hemochromatosis (HFE)-gene (previously called HLA-H gene) in 1996. In the vast 
majority of cases the mutation is a single base change that results in the substitution 
of tyrosine for cysteine at position 282 of the HFE protein (C282Y) 4. However, we 
now know hemochromatosis to be genetically heterogeneous. Next to HFE-related 
hemochromatosis (Online Mendelian Inheritance in Man (OMIM) type 1), two 
additional adult forms are now known to be due to mutations in the transferrin 
receptor 2 (TfR2, OMIM type 3) and ferroportin (SLC40A1, OMIM type 4) genes, 
respectively 1,5. Juvenile hemochromatosis (JH) is an autosomal recessive disease 
that affects young patients and leads to severe clinical complications. JH results from 
mutations of either the hemojuvelin (HJV) gene (OMIM type 2A) or the hepcidin 
antimicrobial peptide (HAMP) gene (OMIM type 2B) 1,6,7. The HAMP gene encodes 
for hepcidin, a small peptide hormone, produced by the liver, and critical for the 
maintenance of body iron homeostasis through blocking ferroportin-mediated iron 
export in intestinal endothelial cells and macrophages 8. Urinary hepcidin levels have 
been found to be low in HFE 9 and TfR2 10mutated adult HH patients, and to be 
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extremely low or even undetectable in HJV and HAMP mutated juvenile cases 9,11,12, 
respectively.  
The majority of subjects homozygous for the HFE-C282Y-alteration present with 
abnormal iron parameters 13, whereas only a small number will manifest clinical 
features 1,5,14-17. Thus, iron loading in HFE-C282Y homozygosity appears to be 
susceptible to the effect of environmental and genetic modifiers. Knowledge of 
modifiers may enable us to better predict those HFE-C282Y homozygous patients 
with an increased risk to develop severe iron overload and, consequently, clinical 
complications 18. The influence of factors such as excessive alcohol intake 19,20, viral 
hepatitis 21 dietary iron 22, or body mass index in women 23 likely explains part of this 
phenotypic heterogeneity in HFE-C282Y homozygosity. Support for HJV as a genetic 
modifier comes from a small number of studies 24,25.  
In 1977, two Dutch families have been reported to be at variance 26 with the 
hypothesis launched by Simon et al 3 and Bomford et al 27 suggesting that the HH 
gene is situated on the short arm of chromosome 6 near the HLA-A locus. One of 
these families, on which we report here, turned out to harbor both HFE and non-HFE-
related forms of HH.  In this extended family 28, we have now identified a new 
truncating mutation in the HJV gene.  
These findings provide us with the opportunity to investigate whether inactivating 
mutations in HJV may have influenced the penetrance of HFE-C282Y homozygosity. 
 
Patients, materials and methods 
Study population and data assessment 
The investigated family has already been described in 1975 28, 1976 29 and 1977 30. 
Findings on liver and serum iron in the early seventies are copied into Table 1. The 
index case in our study (III-54) was born in 1956 and diagnosed in 1972 with 
increased serum iron values and heavy iron accumulation in the hepatocytes 28. 
Subsequently 16L blood could be withdrawn without a fall of serum iron was noted.  
There was no apparent consanguinity between his parents or grandparents 28. Late 
2005, he provided contact information on family members from three branches, in 
which the presence of clinical hemochromatosis was apparent. The institutional 
review board approved this study and informed consent was obtained from all 
participating individuals (N=20). Participants filled out a self-administered 
questionnaire on demographics, lifestyle factors, general medical history, and 
medical history for HH and family structure, including morbidity and mortality. Non-
fasting blood and urine samples from all subjects were collected between 7 and 9 
p.m. on the same day. Blood samples were analyzed for the HFE and HJV 
genotypes, current transferrin saturation (TS) percentages, and ferritin values. In 
urine, creatinine and hepcidin levels were determined. We additionally asked patients 
undergoing phlebotomies to estimate how many phlebotomies were carried out, since 
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in these individuals TS and ferritin values are uninformative as indicators for the 
severity of the disease. 
 
Table 1. Descriptive data on iron parameters of the relatives, sorted by HJV- and HFE-genotype. 
 
     Current  1970s 
C
ode
a
S
ex 
Y
ear of B
irth 
H
FE
 
genotype 
H
JV
 
genotype 
TS
, %
 
Ferritin µg/l 
U
rinary 
hepcidin, 
M
 Int/m
m
ol 
creat 
Iron 
d/A
ge
b, 
rem
ove
g/years 
TS
, %
 
D
FO
-t
Μ
m
ol est c
B III-54 de M 1956 Ht Ho 87 56 0.04 i 1.02 93 159 j
B III-7 e F 1943 Ho Ht 53 76 2.50 0.23 53 32.3 
B III-12 ef F 1951 Ho Ht 71 36 0.60 i 0.53 89 32.9 
B II-12 e M 1924 Ho Ht 60 96 0.83 0.37 86 107 k
B III-85 e  M 1950 Ho Ht 21 30 0.10 i 0.36 83 36.9 
B III-86 g F 1953 Ho Ht 58 147 1.56 0.12 85 45.0 
B III-2 F 1937 Ht Ht 30 304 2.98 n.a. 
n.a. 
44 19.0 
B III-5 F 1940 Ht Ht 27 185 6.12 38 28.0 
B III-10 F 1947 Ht Ht 29 107 2.91 n.a. 40 17.1 
B III-48 M 1943 Ht Ht 34 190 8.30 n.a. 43 19.1 
B III-50 M 1945 Ht Ht 23 30 0.04 n.a. 35 31.2 
B III-52 f F 1949 Ht Ht 46 62 0.75 n.a. 46 17.6 
B III-87 M 1956 Ht Ht 23 351 6.32 n.a. 55 22.0 
B III-3 f F 1938 Ho Wt 65 354 1.93 0.89 87 46.0 
B III-88 eh M 1959 Ho Wt 39 53 0.31 0.30 57 21.1 
B III-89 eh M 1959 Ho Wt 51 87 1.06 i 0.28 
n.a. 
54 23.2 
B III-1 F 1936 Ht Wt 24 275 5.35 41 16.8 
B III-4 M 1939 Ht Wt 18 310 7.77 n.a. 45 28.8 
B III-11 F 1949 Ht Wt 24 56 2.07 n.a. 38 29.5 
B III-9 f M 1946 Wt Wt 58 821 5.13 n.a. 40 17.1 
Reference values 
Men 
Women<50 years 
Women>50years 
<50  
15-280 
  6-80 
15-190 
0.52-7.83 l
 
n.a. <50 <30.3 
 
Ho,homozygous for the mutation; Ht,heterozygous for the mutation; Wt,wildtype for the mutation. N.a.,not 
applicable. CRP (<10 mg/l), Hb (M:8.1-10.7 mmol/l; W:7.3-9.7 mmol/l), MCV (M:84-103 fl; W:85-104 fl) and ALAT 
(<45 U/l) are within reference values for all individuals, except for male II-12 who’s Hb was fairly high (11.5 
mmol/l) and for male III-50 whose ALAT was slightly increased (48 U/l). a These are the codes as used before2, 
roman numerals indicate the generation. b Grams of  iron removed were calculated by multiplying the number of 
phlebotomies by 0.20 g (assuming 500 ml whole blood was withdrawn per phlebotomy). c Urinary iron 
concentration in 24 hrs after administration of 1000 mg Desferrioxamine intramuscular (DFO-test).d Proband; the 
proband in the studies in the early 70s was his sister (Ba, III-513) who was born in 1947 and died in 1998 (1970s: 
TS: 78%; DFO-test: 376 µmol; Liver iron content: 64.2 mmol/100 gram dry weight). e Currently on maintenance 
therapy with phlebotomies. f Alcohol consumption>15 units per week. g Phlebotomized in the past.h III-88 and III-
89 are monozygotic twins.i Date of last phlebotomy less than 4 weeks in the past or unknown.j Liver iron content: 
32.4 mmol/100 gram dry weight.k Liver iron content: 17.1  mmol/100 gram dry weight.l Based on the range of 
values observed in 20 healthy individuals 9. 
 
Iron parameters 
The serum ferritin was measured by a solid phase, two-site chemiluminescent 
immunometric assay (Immulite 2000, Diagnostic Products Corporation, Cirrus). Using 
an Abbott Aeroset analyzer, we measured total serum iron and Unsaturated iron 
binding capacity (UIBC) by the ascorbate/FerroZine colorimetric method (Roche 
Diagnostics). Serum TS (%) was calculated as follows: [serum iron/(serum iron + 
UIBC)] x 100%. The patient estimated the number of phlebotomies and grams of iron 
removed were calculated by multiplying the number of phlebotomies by 0.20 g 
(assuming 500 ml whole blood was withdrawn per phlebotomy). For standardization 
purposes this number was divided by the age of the patient (iron removed/age)31. 
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Since hepcidin levels could be a useful parameter for assessing the severity of HH 1, 
we measured urine hepcidin by a recently described surface enhanced laser 
desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) method with 
the use of IMAC30 ProteinChip arrays 9. 
 
Genetic testing 
HJV-genetic testing results were obtained from routinely used genetic tests. 
Amplimers were designed to incorporate all known coding sequences and exon-
intron boundaries and 5’and 3’ untranslated region of the HJV gene. For sequencing, 
we used the sets of primers reported by Lee et al 32. However, we developed new 
primers for exon 3; therefore all primers used are reported in Table 2 (GenBank NT-
004434 / gi 88943080). 
PCRs were performed in 25-µl reaction volume containing 30 ng genomic DNA, 2.5 
µL PCR II buffer, 2.5 µL MgCl2 (25mM), 0.5 µL dNTPs (2.5 mM), 0.1 µL of each 
primer (50 µM) and 1 unit Amplitaq Gold (Applied Biosystems, The Netherlands). 
PCR reactions were performed in a GeneAmp Thermal Cycler 9700 (Applied 
Biosystems, The Netherlands) under the following conditions: 95ºC 10 minutes, 35 
cycles of 95ºC 30 seconds, 60ºC 45 seconds, 72ºC 1 minute, and a final step of 72ºC 
7 minutes. Before sequencing, PCR products were run on 2 % agarose gel and 
purified using ExoSAP-IT (Amersham Biosciences, Sweden). Products were 
sequenced using the Big Dye Terminator (version 3) cycle sequencing kit (Applied 
Biosystems, The Netherlands) and analyzed on an ABI 3730 automatic sequencer 
(Applied Biosystems, The Netherlands). 
To investigate the novel HJV gene alteration, a restriction fragment length 
polymorphism (RFLP) analysis was developed using 2202F and 2603R primers and 
the restriction enzyme HpyCH4V® (New England Biolabs). In case of the mutation 
one of the restriction sites disappears. The presence of this newly discovered 
mutation in family members and in 53 randomly chosen controls was investigated.  
 
       Table 2. Primers used for amplification of the HJV gene   
         
HJV Primer sequence Fragment size, bp 
HJV Ex 1  F GTACTCTGGCCAGCCATATACT 286 
HJV Ex 1  242R CGAGAGACATCCAAGTAGGTGT  
HJV Ex 2  1297F ATCTCCCCAAATTCCAGTCTG 359 
HJV Ex 2  1655R ACATAGCAGCCTACCCTCTAG  
HJV Ex 3a 1935F   GCAAACTACACTCCGATAGAG 319 
HJV Ex 3a 2253R  GCTGGATCATCAGGTCTTCG  
HJV Ex 3b 2202F GACCTCGCCTTCCATTCG 402 
HJV Ex 3b 2603R GAATCTCATGAGGTGGATCGG  
HJV Ex 4a 2929F TAGTCCTGCATCTCTACTTGG 394 
HJV Ex 4a 3322R TGCAGGTCCTGTTCAGCTG  
HJV Ex 4b 3136F ATGGAGGTGACCGACCTGG 374 
HJV Ex 4b 3509R AGCTGCCACGGTAAAGTTGG  
HJV Ex 4c 3257F GCTCTCCTTCTCCATCAAGG 430 
HJV Ex 4c 3686R AAACTAGTAATGGGACTGATGG  
HJV Ex 4d 3624F TCTGGGCTCTTTGTTCTGTG 407 
HJV Ex 4d 4030R GTCTTCTGCTTTCAGCTCTTG  
HJV Ex 4e 3944F ATAAGTTTAGAGGTCATGAAGG 404 
HJV Ex 4e R GCCCTCTTTCAGTGGAGTG  
        Primers as reported by Lee et al. 32 were used, except for exon 3 primers. 
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Statistical analyses 
We compared serum iron indices, the estimated quantity of iron removed (iron 
removed/age in g/year) by bloodletting and urine hepcidin values between groups of 
genotypes using Mann-Whitney U-tests. 
 
Results 
Hepcidin levels as a first screen for the presence of HH in the index case 
We decided to evaluate hepcidin levels in a patient (index case: III-54) with 
unexplained severe early onset hemochromatosis. This is according to the strategy 
proposed previously in applying the urinary hepcidin analysis as a screening test for 
the presence of HH and its various OMIM types 1. We found urinary hepcidin-25 
levels of 0.04 Mega Intensities / mmol creatinine (M Int/mmol creat) in the index case 
(detectable but extremely low). This value is clearly below the range observed for 
HFE-mutated cases (0.08-4.50) and well below the reference range (0.52-7.83)9. This 
led us to sequence the hemojuvelin (HJV) and HAMP (hepcidin) genes.  
 
Discovery of a novel HJV mutation 
We observed a novel homozygous mutation in exon 3 of the HJV gene. The 494T>A 
transversion led to a premature stop codon at position 165 of the HJV protein: L165X. 
The position of this alteration is depicted in Figure 1. In addition, the index case is 
also a carrier of HFE-C282Y. Mutations in the HAMP gene were absent. 
 
 
Figure 1. Position of L165X truncating mutation in HJV. Schematic representation of functional 
protein domains and the position of the L165X truncating mutation in HJV. Amino-terminal 
secretory signal peptide (SP) and carboxyl-terminal GPI signal peptide (GPI SP), which are removed 
during the cell surface sorting of HJV are indicated by black boxes. Grey boxes indicate HJV domains 
showing homology with repulsive guidance molecule domains. The position of an RGD motif, possibly 
involved in receptor-ligand interactions33, and a partial von Willebrand factor type D (vWF tD) are 
shown. Although autocatalytical processing of the GDPH sequence (between Asp and Pro residues) 
has been documented, HJV remains one molecule after this cleavage by one or several disulfide 
bridges between both polypeptides34. Note that the truncated HJV-L165X product lacks the GPI 
anchor sequences for cell surface retention. 
 
 
Family study 
Since HH was common in this family, we decided to investigate relatives of our index 
case for mutations in the HFE gene and the novel HJV mutation. Past and current 
descriptives are shown in Table 1.  In the family tree the mutational status of the 
HFE-C282Y and the HJV-L165X alteration are shown (Figure 2, page 126). 
Homozygosity for the HJV-L165X alteration was only present in the proband, while 
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heterozygosity was common among his relatives (allele frequency: 14/40=35.0%). 
The novel HJV-L165X alteration was absent among 53 population controls. 
Furthermore, the HFE-C282Y mutation was observed frequently in this family (allele 
frequency: 27/40=67.5%). Phlebotomies were reported only in individuals 
homozygous for either the HJV-L165X (N=1; proband) alteration or the HFE-C282Y 
(N=9) alteration and never in heterozygous persons (Table 1).   
 
Hepcidin assay 
Hepcidin-25 was measured in urine samples from investigated family members 
(Table 1). As a reference we used the range of hepcidin-25 values obtained from 
normal controls (range as measured in 20 persons: 0.52-7.83 9). The older brother 
from our index case also had very low hepcidin levels, which does not seem to be 
explained by his heterozygosity for both the HJV-L165X and the HFE-C282Y 
mutation (III-50, Figure 2, page 130). However, it may be associated with his 
relatively low ferritin levels that may reflect low iron stores, but that had no effect on 
hemoglobin levels yet. There are two other relatives with low hepcidin values (III-85 
and III-88); both of whom are diagnosed with HFE-related HH. There are 6 family 
members who reported being diagnosed with HH with hepcidin levels in the normal 
range. Finally, one individual was found with a relatively high hepcidin level (III-48), 
without a clear explanation. In all other samples, urine hepcidin values were within 
the normal range. In HFE-C282Y homozygotes, we observed substantially lower 
urinary hepcidin levels compared to those in HFE-C282Y heterozygotes (P=.01) 
(Figure 3). 
 
Figure 3. Boxplot showing urinary hepcidin-25 levels (minimum, p25, median, p75, and 
maximum) for different genotypes. HFE-homo: homozygous for the C282Y mutation in the HFE 
gene; HFE-hetero: heterozygous for the C282Y mutation in the HFE gene (compound heterozygotes 
are excluded); HJV-ht: heterozygous for the L165X mutation in the HJV gene; HJV-wt: wildtype for the 
L165X mutation in the HJV mutation. 
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HJV-L165X as a modifier of HFE-related HH 
Iron indices, iron removed/age and urinary hepcidin levels were similar for HJV 
heterozygotes (L165X) and the HJV-wildtypes, also when stratified by HFE genotype 
(Figure 3). In this large family the presence of the HJV-L165X mutation does not 
aggravate the phenotypic appearance of HFE-related hemochromatosis, nor does 
the co-existence of the heterozygous HJV-L165X and the heterozygous HFE-C282Y 
mutation lead to iron accumulation. 
 
Discussion 
A novel truncating mutation (HJV-L165X) was found to be responsible for the non-
HLA linked hemochromatosis described 30 years ago in a Dutch family 26,28,29. The 
family now appears to harbor various combinations of the HFE-C282Y and the HJV-
L165X alterations.  
The early stop codon created by the HJV-L165X mutation may very well lead to 
nonsense-mediated decay of the corresponding messenger RNA. If the aberrant 
message is translated, however, it codes for a protein that lacks the GPI anchor 
signal, such that the potential of HJV to associate with the membrane will be 
completely absent. In both cases, it can be anticipated that the regulation of HJV 
release by muscle cells, and thus regulation of body iron homeostasis, is severely 
impaired in these patients. Thus far, about 25 different mutations have been detected 
in the HJV gene clustered in exons 3 and 4. Several of these mutations result in a 
premature truncation 35,36. 
The identification of HFE-related modifiers will contribute to the debate on whether 
population screening for HH should be undertaken or whether alternative strategies 
should be implemented to improve early detection 5. One popular approach is the 
screening of relatives of a clinically overt HFE-C282Y-homozygous proband 37. This 
family (cascade) screening may become even more cost-effective if a dominant 
modifying factor can be identified. So far, however, the long sought genetic modifier 
that explains the highly variable clinical expression of HH in subjects homozygous for 
the C282Y-mutation has not been found. Nevertheless, some support for genetic 
modifiers comes from several cases in which the interaction of the homozygous HFE-
C282Y with heterozygous mutations in hepcidin resulted in more severe iron 
overload than in HFE-C282Y homozygous patients matched for age and gender 25. 
Another recent and illustrative example of digenic inheritance is the juvenile 
phenotype that results from compound HFE-C282Y/H63D heterozygosity in 
combination with homozygous TfR2 missense mutations 38. These findings appear to 
fit to the experimental evidence that HFE and TfR2 pathways share parts in common 
39. 
Earlier papers suggest that HJV-mutations may also modify the penetrance of HFE-
C282Y homozygotes 24,25: in a cohort study of 310 HFE-C282Y homozygous 
patients, nine patients were found with an additional HJV missense mutation in the 
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heterozygous state (L101P, S105L, E302K, G320V, N372D or R335Q). The iron 
indices of eight patients appeared to be more severe than those observed in HFE-
C282Y homozygous patients of identical sex and similar age ranges 25. In another 
study, 136 HFE-C282Y homozygous, 43 heterozygous, 42 HFE-C282Y/H63D 
compound heterozygotes, and 62 control subjects were scanned for mutations in the 
HJV gene. In one compound heterozygous patient with a severe phenotypic 
presentation, a novel heterozygous HJV-N196K mutation was found 24. In yet another 
study, no modifying effect was observed. In the latter, two patients presented with a 
coinheritance of a homozygous HJV-G320V mutation, and a heterozygous HFE 
mutation. Five of eleven family members carried at least one of the three most 
common HFE mutations (C282Y, H63D or S65C) and were heterozygous for the 
HJV-G320V mutation. None of these 5 individuals had any clear evidence of iron 
loading 40. 
Our data indicate that the HJV-L165X mutation is no apparent modifier of C282Y 
mutation in the HFE-gene, based on serum parameters. We should emphasize 
however, that as most family members had been adequately phlebotomized, serum 
iron parameters were not appropriate as a measure of the iron burden. We found an 
alternative in the retrospective assessment of the quantity of iron removed by 
phlebotomy throughout the years (iron removed/age) 31. Although this approach may 
have some shortcomings in that iron intestinal uptake may increase upon enhanced 
iron intake and by the phlebotomy itself, it offers a rough and second best estimate of 
the severity of the hemochromatosis. Also, results on TS-measurement and the DFO-
test performed in the early 70s before treatment confirm the absence of a clinically 
relevant modifying effect of the HJV-L165X mutation. Finally, in addition to this 
conventional assessment of iron burden, we also analyzed the hepcidin-25 levels in 
urine with our novel MS assay 9. Through both experimental and clinical studies 
hepcidin has been proposed as the unifying pathogenetic factor in HH, and its 
concentration to be inversely correlated to the severity of the phenotype1. Indeed, we 
found statistically significant lower urinary hepcidin levels in HFE-C282Y 
homozygotes in comparison to HFE-C282Y heterozygotes. On the other hand, and in 
line with the observed conventional iron parameters, the similarity in hepcidin levels 
between HFE-C282Y mutated subjects with or without the newly identified 
heterozygous HJV mutation, provides up to date evidence that the truncated 
hemojuvelin has no impact on the penetrance of the HFE-mutation. Last but not 
least, it should be noted that against a background of multiple small variations, 
environmental variation and unknown genes, we cannot exclude a minor effect of the 
HJV-L165X mutation on the iron homeostasis. But if present, this effect is expected 
to be of low clinical relevance. 
The homozygous HJV-L165X truncating mutation predisposes to an aggressive form 
of hemochromatosis, which presents at a young age. Early recognition of this rare 
form of hemochromatosis is of prime importance because timely treatment can 
prevent organ damage and can preserve fertility, as illustrated by our index case, 
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who was followed for 30 years. We assessed both conventional iron parameters (TS 
and ferritin), as well as results from a DFO-test, iron removed/age and hepcidin 
levels, partly before and sometimes long after normalization of iron load by 
phlebotomy in an extended family in which the HFE-C282Y and the HJV-L165X were 
shown to co-exist. We found that the presence of the heterozygous HJV-L165X 
mutation does not clearly aggravate the phenotypic appearance of HFE-related 
hemochromatosis. This indicates that one wildtype copy of HJV is sufficient for HJV-
mediated regulation of iron metabolism and that one mutated or absent copy of the 
hemojuvelin protein is not a clinically relevant modifying factor for the penetrance of 
the homozygous HFE-C282Y mutation. These findings are in agreement with the 
view recently proposed by Anderson and Frazer 41 in which HFE and HJV each are, 
at least in part, participants in distinct regulatory pathways. 
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Summary, conclusions and perspectives 
 
Although iron is essential for life, its reactive properties require tight regulation in 
order to prevent pathological side effects. Hepcidin, a liver produced peptide 
hormone, is thought to be the central regulator of body iron metabolism. Its 
production is foremost under control of erythropoietic activity of the bone-marrow, the 
amount of circulating and stored body iron, and inflammation. Hepcidin exerts its 
regulatory function on iron metabolism by binding to the transmembrane iron exporter 
ferroportin present on macrophages, the basolateral site of enterocytes, and 
hepatocytes. As a result, internalization and degradation of ferroportin prevents iron 
release into the circulation. Although hepcidin was first discovered in human urine 
and serum, most evidence on hepcidin regulation and mode of action comes from in 
vitro work and mice studies that often use hepcidin mRNA expression as a read out. 
Human studies were largely impeded because suitable hepcidin assays were not 
available except for the one documented specific immuno-dot assay to measure 
hepcidin in urine. The major aim of this thesis was the development of a high 
through-put assay for hepcidin in order to study the regulation of this peptide, and to 
gain knowledge on the role of hepcidin in iron metabolism. 
 
Chapter 2 reports an alternative approach for quantification of hepcidin in urine by 
surface-enhanced laser desorption/ionization time-of-flight mass spectrometry 
(SELDI-TOF MS). By this technique we circumvented the difficulties 
immunochemical-based methods encountered due to technical problems of antigen- 
and antibody production. The MS-based assay showed to be capable of detecting the 
3 isoforms of hepcidin normally found in urine from which the identity of the peptide 
peak equivalent to the 25 amino acid peptide (hepcidin-25) was confirmed with a 
commercially available synthetic human hepcidin-25 peptide. Validation of the 
method by analyses of samples with various hepcidin levels showed a strong 
correlation with the immuno-dot assay. We concluded that this new urinary hepcidin 
assay might become an important tool in future studies. 
 
Further improvements of the assay protocol and the use of a different ProteinChip 
array type made it also possible to measure hepcidin in serum as described in Chapter 
3. This time, state of the art proteomic techniques confirmed that next to the three 
hepcidin isoforms in urine, hepcidin-25 in serum had the same amino-acid sequence 
as the 25 amino acid peptide found in urine. The analytical performances were 
acceptable although further improvements were warranted such as the use of an 
internal standard in order to eliminate matrix differences and to allow quantification of 
hepcidin levels. Preliminary validation of both serum and urine application showed to 
be capable of differentiation of various disorders of iron metabolism, this despite 
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influence of pre-analytical and biological variations. Urine hepcidin turned out to be 
more affected by multiple freeze-thaw cycles and storage conditions, but less 
influenced by diurnal variation, than is serum hepcidin. Standardized sampling for 
serum hepcidin analyses was therefore advised when used in future clinical studies.  
 
Chapter 4 describes that the knowledge of hepcidin regulation gained by in vitro 
studies was translatable to the human in vivo situation. Therefore we measured 
soluble transferrin receptor (sTfR) and transferrin saturation (TS) as biochemical 
markers reflecting erythropoietic activity and the iron store regulatory pathways of 
hepcidin, respectively, and C-reactive protein (CRP) as reflector of inflammation 
related regulation in patients with iron metabolism disorders and controls. In parallel 
serum hepcidin-25 and prohepcidin were also assessed. These regulatory pathway 
reflecting parameters were also combined in an algorithm that turned out to predict 
accurately the actual measured hepcidin levels. We concluded that despite the small 
setting of the study and the simplified approach of the algorithm, the complex 
regulation of hepcidin can be determined mainly by these three regulatory pathways. 
In future studies the robustness and suitability of this algorithm in combination with 
actual measured serum hepcidin levels in clinical differentiation has to be validated, 
as potential tool to gain insight in the balance between the regulators and the 
production of hepcidin in specific iron metabolism disorders. 
The role of sTfR as communication factor between the bone marrow and the liver 
was suggested but not proven by the HepG2 expression results which showed an 
inverse association between hepcidin and sTfR. Because of the use of patient serum 
in these in vitro experiments, influence of other components on hepcidin expression 
in the cells could not be excluded. The use of purified sTfR in the same experimental 
setting might clarify the regulatory effect of this plasma protein on hepcidin 
expression.  
 
Chapter 5 describes the effects of lipopolysaccharide (LPS) as an upstream 
inflammation activator on urinary hepcidin excretion levels in a 24-hour time course 
analysis with the use of an in vivo human endotoxemia model. Previous studies had 
shown that interleukin-6 (IL-6) mediated hepcidin increase and consequent 
hypoferremia during inflammation. The temporal associations between plasma 
cytokines, hepcidin levels, and serum iron parameters in healthy individuals after LPS 
injection displayed a dramatically induction of IL-6 within 3 hours after injection. 
Consequently, urinary hepcidin levels peaked within 6 hours, followed by a significant 
decrease in serum iron. This study confirmed the importance of the IL-6-hepcidin axis 
in development of hypoferremia in inflammation and highlighted the rapid 
responsiveness of this iron regulatory system. 
 
Next to the putative role of hepcidin in the redistribution of iron between the intra- en 
extra-cellular body compartments during inflammation, in vitro studies suggested also 
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 involvement of nitric oxide (NO). Chapter 6 describes a study in which the course of 
iron parameters, cytokine profiles and urine hepcidin levels were compared in a 
human in vivo endotoxemia model in the absence and presence of  the selective 
inducible NO synthase (iNOS) inhibitor aminoguanidine. It was shown that CRP, 
Tumor necrosis factor-α, and IL-10, urinary hepcidin excretion levels and circulating 
iron levels showed no significant differences between both experimental settings. 
Therefore we concluded that, compared to hepcidin, NO plays no role of significance 
in body iron homeostasis during systemic inflammation in vivo. 
 
Chapter 7 describes the use of urinary hepcidin analysis as tool to support the search 
for genetic mutations in a patient suffering of non-HFE hereditary hemochromatosis 
(HH). The very low hepcidin levels found in the proband suggested sequencing of the 
hepcidin (HAMP) and hemojuvelin (HJV) genes. As a result, a new homozygous 
truncating mutation, L165X, of the HJV gene was found. These data exemplify that 
hepcidin analysis might have a role as a diagnostic test for HH, provided that 
abnormalities in liver functions, inflammation and a short interval between sample 
collection and phlebotomy are excluded. Therefore, assessment of hepcidin values 
might reduce the workload and costs of the cumbersome procedures of screening for 
sequence variations in the multiple genes responsible for hemochromatosis.  
 
In addition, Chapter 1 suggests several differential diagnostic and therapeutic 
implications of hepcidin analysis. Recognition of iron deficiency anemia (IDA) in the 
context of anemia of chronic disease (ACD) is currently performed with routine 
biochemical parameters which all have their own disadvantages. In contrast to 
increased levels of hepcidin in ACD, classic IDA in man is associated with low 
hepcidin levels which make hepcidin a potential marker for detection of IDA in ACD. 
However, studies in anemic patients suffering from diseases such as rheumatoid 
arthritis, inflammatory bowel diseases, cancer, and end stage renal disease are 
needed to validate the potency of hepcidin measurements under these conditions.  
In iron loading anemias such as thalassemia, studies have suggested hepcidin or 
hepcidin/ferritin index values at the lower end of reference range as a result of 
suppressed hepcidin production due to high and less effective erythropoietic activity. 
These findings may be relevant in the search for non-invasive measures of iron 
burden and improved therapeutic interventions for these often congenital diseases. 
To date, the forecast how patients will react on erythropoietin (EPO) treatment is 
complicated by the co-existence of several factors that contribute to anemia, such as 
inflammatory activity and liver toxic therapy. Determination of hepcidin levels might 
turn out to be of value in the prediction of a response as well as in the monitoring of 
EPO treatment in these patients.  
Additional investigations are warranted to determine hepcidin levels in chronic kidney 
disease, end stage renal disease, upon hemodialysis and EPO and/or iron treatment 
in relation to iron and inflammatory status and blood counts. These studies will pave 
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the way for novel diagnostic and more optimized therapeutic strategies in patients 
treated with EPO.  
In conclusion, improved hepcidin assays are expected to increase insight in 
circulating hepcidin levels in various conditions and its kinetics. This knowledge aids 
in the development of hepcidin agonists and antagonists or the targeting of other 
proteins of the hepcidin regulatory circuitry pathways that will then be of value in the 
treatment of these iron related disorders. 
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Samenvatting in het 
Nederlands 
 Samenvatting, conclusies en beschouwingen 
 
 
Het element ijzer is onlosmakelijk verbonden met de levende cel door de essentiële 
reacties die het vervult in die cel. Dezelfde chemische reactiviteit van het ijzer vraagt 
echter om een zorgvuldige regulatie van dit element om te voorkomen dat eventuele 
toxische neven reacties tot schade in die zelfde cel kunnen leiden. In hoofdstuk 1 
wordt in een overzicht beschreven dat het, door de lever geproduceerde, eiwit 
hormoon hepcidine een centrale rol vervult in de regulatie van het totale 
lichaamsijzer. De productie van hepcidine staat op zijn beurt voornamelijk onder 
controle van de rode bloedcel aanmaak in het beenmerg, de hoeveelheid circulerend 
en opgeslagen lichaamsijzer en ontstekingsactiviteit in het lichaam. Hepcidine 
reguleert de opname en afgifte van ijzer door binding aan ijzer exporterende eiwit 
ferroportin dat zich in de celmembraan van darm epitheelcellen, levercellen en 
macrofagen bevindt. Als gevolg van deze binding verdwijnt de ijzertransporter van de 
celmembraan waardoor er geen ijzer meer afgegeven kan worden aan het bloed. 
Ondanks het feit dat hepcidine voor het eerst ontdenkt is in het serum en urine van 
de mens, is de meeste kennis over de regulatie en werking van dit eiwit verkregen uit 
laboratoriumstudies met muizen en celkweken waarbij DNA of RNA uit (lever)cellen 
wordt gebruikt om een indruk te krijgen van de hepcidine productie. Studies in de 
mens worden beperkt door deze arbeidsintensieve en belastende manier van 
monsterafname. Daarnaast was er tot voor kort maar één immunochemische test 
beschreven waarbij met behulp van antilichamen gericht tegen het hepcidine de 
concentratie van dit eiwit in urine gemeten kon worden. Het belangrijkste doel van dit 
proefschrift is dan ook het ontwikkelen van een hepcidine bepaling in serum of urine 
waardoor studies naar regulatie van dit eiwit en inzicht naar de rol binnen de 
ijzerstofwisseling in de mens vergroot kunnen worden. 
 
Hoofdstuk 2 beschrijft een testmethode om hepcidine in urine te meten met behulp 
van surface-enhanced laser desorption/ionization time-of-flight massaspectrometrie 
(SELDI-TOF MS) na voorscheiding op een analyse chip met specifieke 
bindingseigenschappen. Door het gebruik van massaspectrometrie (MS) wordt het 
gebruik van antilichamen tegen hepcidine, en dus de technische problemen om ze te 
maken omzeild. De nieuwe MS-methode blijkt in staat drie verschillende vormen van 
het hepcidine eiwit te detecteren in urine waarbij het eiwit met een lengte van 25 
aminozuren (hepcidine-25) dat betrokken is bij de ijzerregulatie geïdentificeerd is aan 
de hand van de massa die overeen komt met een commercieel verkrijgbaar 
synthetisch product van humaan hepcidine-25. 
De hepcidine concentraties gemeten met de MS-methode komen sterk overeen met 
de resultaten verkregen met de eerder genoemde immunochemische test. Op basis 
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van deze resultaten is geconcludeerd dat deze nieuwe MS-methode voor metingen 
van hepcidine in urine goed bruikbaar is voor toekomstige studies.  
 
Zoals beschreven is in hoofdstuk 3, maakt verdere verbeteringen van het 
meetprotocol en het gebruik van een analyse chip met een ander type 
bindingsoppervlak het uiteindelijk mogelijk ook hepcidine te detecteren in serum. 
Door middel van hoogwaardige massa spectrofotometrische scheidingstechnieken is 
aangetoond dat het in serum detecteerbare hepcidine-25 dezelfde 
aminozuurvolgorde heeft als het hepcidine dat in urine gemeten wordt. De 
analytische prestaties van deze nieuwe testmethode zijn acceptabel. Echter, het 
gebruik van een interne standaard zou de testmethode verder kunnen verbeteren 
omdat daardoor de invloed van de verschillen in samenstelling tussen serum en urine 
worden geëlimineerd en kwantificering mogelijk wordt. De eerste studies met zowel 
serum als urine metingen laten zien dat onderscheid tussen verschillende 
ijzergerelateerde aandoeningen mogelijk is ondanks invloed van opslag en 
biologische dagvariaties op de uitslag. Hepcidine in urine blijkt namelijk meer 
beïnvloed te worden door veelvuldig invriezen en ontdooien en de temperatuur 
waarbij het bewaard wordt, terwijl hepcidine in serum juist onder invloed staat van het 
dag/nacht ritme. Er wordt dan ook voor klinische studies met serum aanbevolen op 
vaste tijden monsters af te nemen, om vergelijking van uitslagen tussen personen 
mogelijk te maken. 
 
Hoofdstuk 4 laat zien dat de kennis met betrekking tot hepcidine regulatie verkregen 
uit laboratorium studies met muizen en celkweken ook toepasbaar is op de regulatie 
in de mens. Hiervoor zijn circulerend serum transferrine receptor (sTfR) en 
transferrine saturatie (TS) gemeten als biochemische merkers voor respectievelijk 
beenmerg activiteit en lichaamsijzer voorraad en het acute fase eiwit C-reactief 
proteine (CRP) als merker voor ontstekingsactiviteit in het lichaam. Elk van deze 
merkers weerspiegelen een proces dat de hepcidine productie beïnvloedt. Gelijktijdig 
zijn tevens hepcidine-25 en het voorlopereiwit prohepcidine in serum gemeten van 
gezonde vrijwilligers en verschillende groepen patiënten met aandoeningen van het 
ijzermetabolisme. Vervolgens zijn deze drie merkereiwitten in een formule 
samengevoegd waarbij na invulling van de in serum gemeten relatieve concentraties 
van elke merker een hepcidine waarde kan worden berekend die nauwkeurig 
overeen komt met de werkelijk gemeten serum hepcidine-25 concentratie. Uit deze 
data is geconcludeerd dat ondanks het beperkte aantal gemeten monsters en de 
eenvoud van de formule, de concentratie van het circulerende serum hepcidine 
voornamelijk bepaald wordt door de drie onderzochte regulatie processen. In 
toekomstige studies zullen de robuustheid en bruikbaarheid van de formule in 
klinische differentiatie gevalideerd moet worden om zo meer inzicht te krijgen in de 
balans tussen de verschillende regulatoren en de werkelijke hoeveelheid hepcidine 
die geproduceerd wordt in ijzermetabolisme gerelateerde aandoeningen. Tevens 
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 wordt in dit hoofdstuk een hepcidine expressiestudie in levercellen beschreven 
waarbij de rol van sTfR als communicatie eiwit tussen het beenmerg en de lever is 
bestudeerd. De resultaten laten een sterke associatie zien tussen de sTfR 
concentratie in serum en de hoeveelheid hepcidine die door de levercellen tot 
expressie worden gebracht. Echter, een direct oorzakelijk verband wordt niet 
bewezen door deze resultaten. Nieuwe experimenten met bijvoorbeeld gezuiverd 
sTfR eiwit kunnen waarschijnlijk meer duidelijkheid geven over de potentie van dit 
eiwit in de regulatie van hepcidine. 
 
Hoofdstuk 5 beschrijft het effect van bacterieel endotoxine op de uitscheiding van 
hepcidine in urine gedurende 24 uur, waneer deze stof ingespoten wordt in gezonde 
vrijwilligers. Eerdere studies hadden al aangetoond dat interleukine 6 (IL-6), een 
hormoon geproduceerd door witte bloedcellen tijdens ontstekingsreacties, in staat is 
de productie van hepcidine te verhogen. Als gevolg hiervan werd een afname van de 
ijzerconcentratie in het bloed gezien. In onze studie wordt 3 uur na injectie van 
endotoxine een sterke toename van IL-6 gemeten, waarop vervolgens een toename 
van hepcidine uitscheiding in urine gezien wordt tot 6 uur na injectie, gevolgd door 
een afname van ijzer in het bloed. Deze data bevestigen dat de IL-6-hepcidine as 
een belangrijke rol speelt bij het ontstaan van ijzergebrek tijdens inflammatie in de 
mens. Tevens illustreert deze studie de hoge snelheid waarmee dit proces 
plaatsvindt.  
 
Naast het effect dat hepcidine op het circulerende ijzer in het bloed heeft tijdens 
infecties, zijn uit diverse laboratoriumexperimenten met celkweken aanwijzingen 
verkregen dat stikstofoxide (NO) hier ook een rol speelt. Dit NO wordt tijdens 
inflammatie geproduceerd door een enzym genaamd “induceerbaar NO synthase 
(iNOS)”. In hoofdstuk 6 wordt een studie beschreven waarbij wederom gezonde 
vrijwilligers met endotoxine zijn ingespoten, nu echter in combinatie met of zonder de 
specifieke iNOS remmer aminoguanidine. Diverse infectie parameters in het bloed en 
urine hepcidine concentraties zijn ook hier gedurende 24 uur vervolgd maar lieten 
geen verschillen zien tussen aan- of afwezigheid van aminoguanidine. 
Geconcludeerd is dat NO minder invloed uitoefent op de ijzerregulatie in het lichaam 
tijdens systemische ontstekingsreacties in de mens, in vergelijking tot hepcidine. 
 
Uit hoofdstuk 7 blijkt dat het meten van de concentratie hepcidine in urine een goed 
hulpmiddel is in de zoektocht naar genen verantwoordelijk voor ijzerstapeling. Dit is 
geïllustreerd aan de hand van een patiënt lijdend aan ijzerstapeling die niet wordt 
veroorzaakt door een genetisch defect van het HFE eiwit. De zeer lage hepcidine 
concentratie gemeten in deze patiënt, wijzen op een mutatie in het hepcidine (HAMP) 
of hemojuveline (HJV) gen. Verder onderzoek leverde dan ook een nieuwe mutatie in 
het HJV gen op, aangeduid als L165X. Deze data laten zien dat de hepcidine meting 
een waardevolle rol kan vervullen als screentest bij genetische ijzerstapeling op 
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voorwaarde dat leverafwijkingen en ontstekingsprocessen zijn uitgesloten en de 
afname van het analysemonster voldoende ruim voor of na een aderlating heeft 
plaatsgevonden. Het meten van hepcidine zou daarmee een gunstig effect kunnen 
hebben op de werklast en onkosten die een uitgebreide genetische screening van 
hemochromatose kandidaat genen met zich mee brengt. 
 
Aanvullend worden er in hoofdstuk 1 diverse suggesties gedaan voor diagnostische 
en therapeutische toepassingen van de hepcidine bepaling. In de eerste plaats zou 
de hepcidine meting een rol kunnen gaan spelen in het herkennen van een 
ijzergebreksanemie tijdens inflammatie. Op dit moment wordt dit gedaan met een 
combinatie van biochemische testen die elk hun eigen tekortkomingen hebben. In 
tegenstelling tot de hoge hepcidine concentraties tijdens inflammatie, worden bij 
ijzergebrek lage hepcidine waarden gemeten, waarmee hepcidine een potentiële 
merker kan zijn bij een combinatie van beide processen. Door meting van 
monstermateriaal van patiënten waarbij zowel ijzergebrek als inflammatie de oorzaak 
kunnen zijn van bloedarmoede zoals in reumatoïde artritis, ontstekingen in het 
maagdarmkanaal, kanker, of ernstige nierziekten, kan inzicht verkregen worden in de 
diagnostische waarde van de hepcidine meting onder deze condities. 
Hepcidine of de hepcidine/ferritine ratio hebben daarnaast in diverse studies laten 
zien dat het goede klinische merkers zouden kunnen zijn voor het schatten van de 
ijzerbelasting bij aangeboren vormen van anemie die gepaard gaan met 
ijzerstapeling. Lage waarden wijzen op een onderdrukking van de hepcidine 
productie veroorzaakt door een sterke, maar inefficiënte, rode bloedcel aanmaak in 
het beenmerg van deze patiënten. Deze bevindingen kunnen relevant zijn voor het 
verkrijgen van een goede maat voor de hoeveelheid ijzer opgeslagen in het lichaam 
zonder belastende ingrepen en voor het verbeteren van behandelingsmethoden voor 
deze vaak aangeboren aandoeningen. 
Als laatste toepassingsmogelijkheid wordt de voorspelling van de reactie op het 
toedienen van erytropoietine (EPO) of het vervolgen van deze therapie genoemd. 
Deze toepassingsmogelijkheden worden momenteel bemoeilijkt door de 
verschillende factoren die bijdragen tot het ontstaan van een anemie bij EPO 
behandelde patiënten zoals ontstekingen en de toediening van lever toxische 
medicijnen. Toekomstig onderzoek zal moeten uitwijzen welke hepcidine waarden 
gevonden worden in patiënten met kanker of chronische nierziekten die behandeld 
worden met EPO en/of ijzerpreparaten in vergelijking tot ijzerwaarden in het bloed, 
infectiestatus en het aantal bloedcellen. Deze studies zullen naar verwachting 
mogelijkheden creëren voor nieuwe diagnostiek en betere therapieën in patiënten die 
behandeld worden met EPO.  
Concluderend kan gesteld worden dat door verbeterde hepcidine analysemethoden 
het inzicht in de regulatie van het eiwit en informatie over de te verwachten 
concentraties onder verschillende condities vergroot zal worden. Deze kennis zal 
bijdragen tot het ontwikkelen van betere diagnostische bepalingen, en de 
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 ontwikkeling van medicijnen die de werking van het hepcidine eiwit of ander eiwitten 
betrokken bij de regulatie van hepcidine kunnen beïnvloeden als nieuwe therapie in 
de behandeling van ijzer gerelateerde aandoeningen.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
116  
  
 
Dankwoord 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Dankwoord 
 
Tja, en dan nu het dankwoord. Misschien wel het moeilijkste deel van het hele 
proefschrift. Niet dat bedanken iets lastigs is, maar je wilt vooral niemand vergeten. 
Hoe klein het aandeel van iemand ook geweest is, en ook al word ik uiteindelijk 
aangekeken op de inhoud, dit proefschrift is voor mij het gezamenlijke resultaat van 
al die mensen die op de één of andere manier de afgelopen 3 jaar betrokken zijn 
geweest bij mijn promotie onderzoek. Daarvoor mijn hartelijke dank. 
 
Uiteraard ontkom ik er niet aan toch een aantal mensen in het bijzonder te noemen. 
 
Allereerst wil ik mijn promotor Hans Willems bedanken voor het mogelijk maken van 
dit onderzoek op de afdeling klinische chemie (AKC) van het UMC St Radboud.  
Tijdens mijn hoofdvak stage op het AKC ben ik waarschijnlijk voldoende betrouwbaar 
overgekomen dat je het zelfs aandurfde me een combinatie traject aan te bieden. Het 
eerste deel, het promotie onderzoek, zit er op, nu nog de interne opleiding tot klinisch 
chemicus verder afmaken. Voorlopig blijf ik dus nog even. 
 
Dorine, geweldig. Ik weet niet hoe je het doet maar onder jouw directe begeleiding is 
onderzoek inspirerend. Ik wist niet dat ik het in me had maar jij hebt blijkbaar de 
onderzoeker in me naar boven kunnen halen. De drive waarmee jij onderzoek bedrijft 
is aanstekelijk, stimulerend en voor mij van cruciaal belang geweest om dit project af 
te kunnen ronden. Ik wil je hiervoor heel erg bedanken. 
Daarnaast wil ik je ook bedanken voor alle gezelligheid gedurende de congressen in 
het buitenland, de vele discussies en je luisterende oor op die momenten dat het 
nodig was. 
 
Natuurlijk wil ik ook jou bedanken, Harold. In de rol van co-promotor heb je menig 
artikel voorbij zien komen voor correctie. Als man van weinig woorden wist je feilloos 
de zwakke punten aan te geven waardoor het uiteindelijke resultaat vele malen beter 
werd. Jouw kennis over eiwitten is van grote waarde gebleken gedurende het 
onderzoekstraject. Ik heb veel van je geleerd, dank hiervoor.  
 
Coby, zonder jou was het niet gelukt. Onze samenwerking en vele discussies hebben 
er voor gezorgd dat de hepcidine analyse is wat ze is. Jouw kennis en ervaring over 
hoe je eiwitten in urine moet benaderen heeft het project een solide basis gegeven. 
Het stond voor mij dan ook snel vast dat jij één van mijn paranimfen moest worden. 
Ik kijk terug op een leuke en succesvolle samenwerking en hoop dat Joyce hetzelfde 
mag ervaren gedurende haar promotieonderzoek.  
 
118  
                                                  Dankwoord                      
Verder bedank ik natuurlijk de research analisten van het eerste uur: Rian en Erwin. 
Het was erg gezellig samen met de vissen en de droppot. De eerste stappen binnen 
het hepcidine werk waren al door jou gedaan, Rian. Blotten met slechte commerciële 
antilichamen bleek uiteindelijk toch niet de weg te zijn om hepcidine aan te tonen 
maar heeft ons veel geleerd over het gedrag van het peptide onder 
testomstandigheden. Later bleek jouw kennis en vaardigheden met de prohepcidine 
ELISA goed bruikbaar. Ik wil je hiervoor nogmaals bedanken. Erwin, naast het vele 
PCR werk van de verschillende ijzer-genen is jouw rol binnen het eiwit werk vooral 
het laatste jaar uitgebreid door de vele externe hepcidine-samenwerkingsprojecten. 
Ik dank je voor je inzet op alle analyses. 
 
Joyce, now it’s up to you. Je hebt het stokje van me overgenomen als junior 
onderzoeker en zult nu ook op zoek moeten naar de krenten in de onderzoekspap. 
Voorlopig zullen we nog veel samen kunnen optrekken, met dezelfde mensen om 
ons heen, in dezelfde stimulerende omgeving. Ik wens je heel veel succes. 
 
Renée. Ik heb jou gevraagd of je naast Coby ook paranimf wilde zijn tijdens mijn 
promotie. Ik heb ervaren dat het goed is een maatje te hebben op de werkvloer, en 
dat ben je. Jouw sociale karakter en de liters koffie die daar bij horen zijn vaak 
onmisbaar gebleken tijdens de eindfase van dit project. Dank hier voor. 
 
April; how unorganized can you be? You improved my English; I didn’t improve your 
Dutch. It was a privilege having you as a colleague, especially at the iron meetings in 
Barcelona, Kyoto and London. Thanks for our intensive and noisy discussions. 
Boukje, dat de epidemiologie zo snel hepcidine zou kunnen gebruiken was voor mij 
een prettige verrassing. Deze toepassing heeft toch maar mooi een publicatie 
opgeleverd: I owe you one.  
 
Jacqueline en Edmée, bedankt voor jullie interesse in mijn project en de tips om het 
tot een goed einde te brengen. Verder alvast bedankt voor de inspirerende 
gesprekken over “het vak”. Ik ben er zeker van dat er nog vele zullen volgen.  
Verder wil ik Annemarie en Siem niet vergeten voor hun getoonde betrokkenheid en 
gezelligheid tijdens de koffie en lunch pauzes – gaan we buiten zitten? 
Alle collega´s van het AKC, ook jullie bedankt voor je soms “persoonlijke bijdrage” 
aan het onderzoek, maar vooral ook voor de interesse naar wat er zich in het 
kenniscentrum afspeelt. 
 
Zonder SELDI geen analyse, vandaar dat ik hierbij zeker de  SELDI-faciliteit wil 
noemen. Arnoud, Mark en Waander, bedankt voor alle ondersteuning tot nu toe. Het 
is ons toch maar mooi gelukt de SELDI een plek te geven binnen het diagnostische 
veld. Dat er nog veel toepassingen mogen volgen. 
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Als ik SELDI zeg, bedoel ik natuurlijk ook Davy. Ik heb zeer goede herinneringen aan 
onze samenwerking in “Het Ciphergen tijdperk”. Jouw kennis en bijdrage zijn tot op 
de dag van vandaag nog voelbaar. 
 
Verder wil ik hierbij alle artsen bedanken die betrokken zijn geweest bij het 
verzamelen van patiënten materiaal voor de verschillende studies. In het bijzonder 
wil ik Peter Pickkers noemen. Het humane endotoxine model wat jij begeleide bleek 
een lot uit de loterij en een bron van materiaal voor vele studies. Onze samenwerking 
heb ik als geweldig inspirerend ervaren, dank hier voor. Ik hoop dat de toekomst nog 
veel mag gaan brengen.  
 
I also like to thank our collaborators from abroad. Specifically I’d like to mention 
Tomas Ganz and Ella Nemeth from UCLA. Working together with the pioneers on 
hepcidin analysis was a privilege. Your contribution to my first papers and the 
donation of peptides and antibodies turned out to be a success. Many thanks for your 
cooperation!  
 
Uiteraard mag ik ook niet de “Nederlandse IJzer Congres Familie” vergeten: Jo Marx, 
Cees van Deursen, Herman Kreeftenberg en Esther Jacobs. Met erg veel pezier 
denk ik terug aan onze congressen. Hopelijk was ik niet te vermoeiend. Volgend jaar 
European Iron Club in Zwitserland? 
 
Ten slotte wil ik familie en vrienden heel hartelijk bedanken voor hun belangstelling 
en steun gedurende dit project. Ik beloof dat mijn gespreksstof in de toekomst weer 
wat meer omvat dan enkel ijzer en hepcidine. 
 
Lieve Ria, we zijn er bijna. Mede door jou is het mogelijk geweest dit traject in te 
gaan waarvan het promotie onderzoek maar een onderdeel is. Ondanks alles ben je 
blijven geloven in dit project en heb je me ondersteund waar mogelijk. Dank je wel, ik 
ben trots op je en heb ongelofelijk veel zin in de toekomst die voor ons ligt. 
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Erwin Hendrikus Johannes Maria Kemna werd geboren op 12 juli 1967 te Almelo. In 
1985 behaalde hij zijn HAVO diploma aan het St. Canisius College te Almelo. In 1985 
begon hij met het Hogere Laboratorium Onderwijs (HLO), medische richting, in 
Hengelo. De stage en afstudeerperiode werden doorlopen op het klinisch chemisch 
laboratorium van het Wezenlanden Ziekenhuis te Zwolle (Dr. K. Miedema en Drs. E. 
van Voost tot voorst). Het HLO diploma werd verkregen in 1989. Na het vervullen van 
de dienstplicht als sergeant-analist in het Militair Hospitaal Dr. A. Mathijssen in 
Utrecht, begon hij in 1990 als klinisch-chemisch analist in het Deventer Ziekenhuis. In 
1992 trouwde hij met Ria Schilder. In 2001 nam hij ontslag in Deventer en begon de 
studie Biomedische wetenschappen aan de Katholieke Universiteit in Nijmegen 
(KUN). Het doctoraal examen met hoofdvakstage Pathobiologie (Prof. Dr. J.L. 
Willems) werd behaald in april 2004. Van mei 2004 tot februari 2007 was hij 
werkzaam als junior onderzoeker op de Afdeling Klinische Chemie (AKC) in het 
Universitair Medisch Centrum St. Radboud te Nijmegen (Prof. Dr. J.L. Willems, Dr. 
D.W. Swinkels en Dr. H. Tjalsma). Tijdens deze periode werd het onderzoek verricht 
dat is beschreven in dit proefschrift. Sinds februari 2007 is hij bij dezelfde vakgroep in 
opleiding tot Klinisch Chemicus. 
 
 
Erwin Hendrikus Johannes Maria Kemna was born on July 12th 1967 in Almelo, The 
Netherlands. After he finished junior high school in 1985, he started a study to 
become a laboratory technician and graduated in 1989 as Bachelor of Science. 
During military service he worked as laboratory technician at the Central Military 
Hospital in Utrecht, The Netherlands. In 1990 he moved to Deventer, The 
Netherlands, to start at the Clinical Chemistry Laboratory of the local hospital. In 
1992 he married Ria Schilder. In 2001 he ended his job in Deventer and started his 
study biomedical science at the University of Nijmegen, The Netherlands. He was 
awarded the degree of Master of Science in April 2004 on a project on folic acid in 
serum and erythrocytes, supervised by Prof. Dr. J.L. Willems. In May of that same 
year he started his PhD project on hepcidin at the department of Clinical Chemistry at 
Radboud University Nijmegen Medical Centre, The Netherlands, until February 2007, 
under supervision of Dr. D.W. Swinkels, Dr. H. Tjalsma and Prof. Dr. J.L. Willems. 
The results from this project are presented in this thesis. In February 2007 he started 
his internships at the same department in order to become a Clinical Chemist. 
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Figure 4, chapter 1, Page 22. An additive hypothetical model of hepcidin regulation in different 
disorders of iron metabolism. The model is based on the evidence provided by studies that are 
referred to in Table 1 (page 24) and that are at least partially described throughout the text of the 
paper. Different conditions of iron metabolism disorders are shown on the right in relation to the 
expected circulating hepcidin levels (second column from the right). The size of every colored box 
indicates the relative contribution of the specific regulator and should be interpreted in relation to the 
box size under normal conditions. In case the regulation pathway is affected by a gene mutation, a 
dotted line is drawn. The sum of all regulators indicates the expected hepcidin level. The erythropoietic 
regulator has a negative effect on hepcidin production and if strong enough is capable to suppress or 
overrule the inductive action of the iron store regulator. This might result in a nett decrease of hepcidin 
production, as occurs in the iron loading anemias, such as thalassemia major. Gene mutations in the 
iron store regulation pathway, such as in HFE or TfR2, reduce the effect of this store regulating 
pathway. This results in a lower hepcidin response than predicted from the elevated body iron stores, 
e.g. inappropriately low hepcidin levels Both, store and erythropoietic activity regulation depend on 
mandatory signaling by HJV/SMAD pathway. In case of disruption of this pathway, e.g. in the presence 
of HJV mutations induction of hepcidin by elevated iron stores is crippled. Finally, in this model 
inflammation acts as an additive regulator and is assumed to increase hepcidin levels regardless the 
activity of the other regulators. 
 
Figure 2, chapter 7, page 98. Family tree showing HFE and HJV gene mutations. 
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Figure 1, chapter 4, page 64/65. Model of pathways involved in hepcidin regulation as basis for 
a predictive algorithm. A) A regulation model constructed from the combined results of recent 
publications6-11, focused on three relevant sites involved in hepcidin regulation: kidney, bone marrow 
and liver cells. It comprises three active regulation pathways and a mandatory signaling pathway that 
together orchestrate the (pro-)hepcidin production by interacting with the hepcidin anti microbial 
peptide (HAMP) gene on chromosome 19q13. In case of hypoxia or anemia, the erythropoietic 
activity derived regulation responds upon low oxygen pressure (pO2) levels that induce hypoxia 
inducible factor (HIF)-1α stabilization in kidney cells,  which results in erythropoietin (EPO) production 
of the kidney. EPO increases the erythropoietic activity and thus the need for iron of the bone marrow. 
Therefore, erythropoietic progenitor cells increase transferrin receptor (TfR)1 up-regulation. 
Communication between bone marrow and the liver is performed by a, thus fare, unknown factor, in 
order to release stored iron and increase absorption by the duodenal enterocytes. This factor might 
negatively interfere in the formation of a hepcidin inducing sensing complex of the store regulation 
pathway which acts upon the liver cells via circulating iron bound to transferrin, or might act by a still 
unknown direct inhibitory pathway. Glycosylphosphatidylinositol (GPI)-linked cell associated 
hemojuvelin (HJV) has been suggested to maintain a mandatory regulation pathway by bone 
morphogenetic protein (BMP)/SMAD signaling. Disruption of this pathway cripples the functionality of 
the erythropoietic activity derived and store regulation. The inflammatory regulation pathway, 
induced by interleukin (IL)-6 followed by Janus kinase (JAK)/signal transducer and activator of 
transcription (STAT)-3 signaling, is suggested to act more dominant regardless the status of the store 
and erythropoietic activity regulation pathways, and the HJV/SMAD pathway. 
B)  Algorithm based on measured TS, sTfR and CRP levels as reflecting parameters for iron store, 
erythropoietic activity, and inflammation respectively, by which relative hepcidin production can be 
estimated.   
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